Canine Pneumovirus: Veterinary Reference

Overview and Taxonomy of Canine Pneumovirus

Introduction to Canine Pneumovirus

Canine pneumovirus (CnPnV) represents a significant, though historically under-recognized, respiratory pathogen within the Pneumoviridae family, a group of enveloped, negative-sense, single-stranded RNA viruses that have garnered increasing attention in both human and veterinary medicine. The virus is most closely related to murine pneumovirus (MPV) and, more distantly, to the human respiratory syncytial virus (HRSV) and bovine respiratory syncytial virus (BRSV), all of which are major causes of respiratory disease in their respective hosts. The emergence of CnPnV as a recognized pathogen in dogs has filled a critical gap in our understanding of the canine respiratory disease complex (CRDC), a multifactorial syndrome that has long perplexed veterinarians due to the frequent inability to identify a causative agent using conventional diagnostic panels. The discovery and subsequent characterization of CnPnV have been propelled by advances in metagenomic sequencing and a growing appreciation for the role of viral co-infections in exacerbating clinical disease. This section provides a comprehensive overview of the taxonomy, genomic organization, structural biology, and evolutionary context of CnPnV, establishing the foundational knowledge necessary for understanding its pathogenesis, epidemiology, and clinical significance.

Taxonomic Classification and Phylogenetic Position

The taxonomic placement of canine pneumovirus is firmly rooted within the order Mononegavirales, a large and diverse group of non-segmented, negative-sense RNA viruses. Within this order, CnPnV is classified under the family Pneumoviridae, which was recently elevated from subfamily status within the Paramyxoviridae family based on significant genetic and structural differences. The Pneumoviridae family is further divided into two genera: Orthopneumovirus and Metapneumovirus. Canine pneumovirus is a member of the genus Orthopneumovirus, which also includes the prototypical human respiratory syncytial virus (HRSV), bovine respiratory syncytial virus (BRSV), and murine pneumovirus (MPV). This classification is supported by phylogenetic analyses of conserved genomic regions, particularly the nucleoprotein (N), phosphoprotein (P), and polymerase (L) genes, which consistently place CnPnV in a monophyletic clade with other orthopneumoviruses.

Phylogenetically, CnPnV is most closely related to MPV, sharing a high degree of sequence identity across multiple genes. This close relationship suggests a possible evolutionary origin from a rodent reservoir, with subsequent host-switching events leading to the establishment of CnPnV in canine populations. The virus is more distantly related to HRSV and BRSV, reflecting a longer period of evolutionary divergence. The genetic distance between CnPnV and other orthopneumoviruses is sufficient to classify it as a distinct viral species, a designation that has been formally recognized by the International Committee on Taxonomy of Viruses (ICTV). The availability of complete genome sequences for multiple CnPnV isolates from geographically diverse regions has enabled detailed phylogenetic analyses, revealing the existence of at least two distinct genetic lineages or clades. These lineages, often referred to as clade A and clade B, exhibit nucleotide sequence divergence of approximately 10-15% across the genome, with higher variability observed in the attachment glycoprotein (G) gene. The presence of these distinct lineages has important implications for diagnostic assay design, vaccine development, and our understanding of viral evolution and immune evasion. The World Organisation for Animal Health (WOAH) has recognized the potential impact of emerging respiratory viruses in companion animals, and the taxonomic characterization of CnPnV is a critical step in establishing surveillance and control measures.

Genomic Organization and Structural Biology

The CnPnV genome is a single-stranded, negative-sense RNA molecule approximately 15,000 nucleotides in length, a size consistent with other orthopneumoviruses. The genome is organized into a linear array of ten genes, each encoding a single major protein, arranged in the conserved order typical of the genus: 3′-NS1-NS2-N-P-M-SH-G-F-M2-L-5′. This gene order is critical for the regulation of viral transcription and replication, with genes located closer to the 3′ end (the promoter region) being transcribed at higher levels than those at the 5′ end. The genome is encapsidated by the nucleoprotein (N) to form a helical ribonucleoprotein (RNP) complex, which serves as the template for both transcription and replication by the viral RNA-dependent RNA polymerase (L) and its cofactor, the phosphoprotein (P).

The structural proteins of CnPnV are highly conserved in function and architecture with those of other orthopneumoviruses. The fusion glycoprotein (F) is a class I viral fusion protein that mediates the entry of the virus into host cells by driving the fusion of the viral envelope with the host cell membrane. The F protein is synthesized as an inactive precursor (F0) that must be cleaved by host cell proteases into two disulfide-linked subunits, F1 and F2, to become fusion-competent. This cleavage is a key determinant of viral tropism and pathogenicity. The attachment glycoprotein (G) is a heavily glycosylated type II transmembrane protein responsible for binding to host cell receptors, primarily glycosaminoglycans such as heparan sulfate. The G protein is the most variable of the structural proteins, and its genetic diversity is the basis for the differentiation of CnPnV into distinct lineages. The small hydrophobic (SH) protein is a short transmembrane protein of unknown function, but it is thought to play a role in modulating the host immune response, potentially by inhibiting the NLRP3 inflammasome. The matrix protein (M) is a non-glycosylated protein that lines the inner leaflet of the viral envelope and is essential for viral assembly and budding. The M2 gene encodes two proteins, M2-1 and M2-2, through overlapping open reading frames. M2-1 is a transcription elongation factor that enhances processivity of the polymerase, while M2-2 is a regulatory protein involved in the switch from transcription to genome replication.

In addition to the structural proteins, the CnPnV genome encodes two non-structural proteins, NS1 and NS2, which are located at the extreme 3′ end of the genome and are therefore expressed at the highest levels early in infection. These proteins are the primary antagonists of the host innate immune response. NS1 and NS2 function cooperatively to inhibit the type I interferon (IFN) signaling pathway by targeting multiple components, including the transcription factors IRF3 and IRF7, and by promoting the degradation of STAT2, a key mediator of IFN signaling. The ability of CnPnV to effectively suppress the host interferon response is a critical determinant of its virulence and its capacity to establish infection in the face of host defenses. The structural biology of the CnPnV virion, as visualized by electron microscopy, reveals a pleomorphic, spherical to filamentous particle approximately 150-300 nm in diameter, with a lipid envelope derived from the host cell plasma membrane and studded with the F and G glycoprotein spikes.

Epidemiology and Host Range

Since its initial identification, CnPnV has been detected in canine populations across multiple continents, including North America, Europe, and Asia, suggesting a global distribution. Epidemiological studies utilizing reverse transcription-polymerase chain reaction (RT-PCR) and serological assays have reported prevalence rates ranging from 5% to 30% in dogs presenting with clinical signs of respiratory disease, and lower rates (2-10%) in apparently healthy dogs. These data indicate that CnPnV is a common component of the CRDC and can circulate subclinically within populations. The virus is most frequently detected in young dogs, particularly those housed in high-density environments such as shelters, boarding kennels, and breeding facilities, where the conditions of crowding and stress facilitate viral transmission. Transmission occurs primarily through direct contact with infected respiratory secretions, as well as through fomites and aerosolized droplets. The virus is relatively labile in the environment but can persist on surfaces for several hours, contributing to its spread in kennel settings.

The host range of CnPnV appears to be restricted to canids, with no evidence of natural infection in other domestic species or humans. Experimental inoculation studies have confirmed that CnPnV can replicate efficiently in the respiratory tract of dogs, causing mild to moderate bronchiolitis and interstitial pneumonia. However, the virus has not been shown to cause disease in other laboratory animals, such as mice or ferrets, suggesting a narrow host tropism. This host restriction is likely mediated by species-specific interactions between the viral G protein and its cellular receptor, as well as by the ability of the viral NS proteins to effectively antagonize the canine interferon system. From a public health perspective, there is currently no evidence that CnPnV is a zoonotic pathogen. The virus is genetically distinct from HRSV, and the species barrier appears to be robust. Nevertheless, the close evolutionary relationship between CnPnV and other pneumoviruses, and the potential for viral evolution and host-switching, warrants continued surveillance. The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) emphasize the importance of monitoring emerging respiratory viruses in animal populations as part of a comprehensive One Health approach to pandemic preparedness.

Genetic Diversity and Evolution

The genetic diversity of CnPnV is a dynamic and evolving area of research. As mentioned, the virus is currently classified into two major genetic lineages, clade A and clade B, based on phylogenetic analysis of the full-length genome or specific gene segments. The G gene is the most divergent region, with nucleotide sequence identity between clades often falling below 85%. This level of diversity is comparable to that observed between different subtypes of HRSV (A and B) and has significant implications for the development of diagnostic tests and vaccines. Serological studies using virus neutralization assays have demonstrated that antibodies raised against one clade can cross-neutralize the other, but the neutralizing titers are often lower against the heterologous clade. This suggests that there may be antigenic differences between the clades, potentially allowing for reinfection with a different lineage even in dogs that have been previously infected.

The evolutionary mechanisms driving CnPnV diversity include the accumulation of point mutations due to the error-prone nature of the RNA-dependent RNA polymerase, as well as recombination events. Although recombination is less common in non-segmented negative-sense RNA viruses than in positive-sense RNA viruses, it has been documented in pneumoviruses and may contribute to the emergence of novel strains. The rate of evolution of the CnPnV genome is estimated to be on the order of 10⁻³ to 10⁻⁴ substitutions per site per year, which is typical for RNA viruses. This relatively rapid rate of evolution, combined with the selective pressure exerted by the host immune system, drives the continuous emergence of new genetic variants. The ongoing surveillance of CnPnV genetic diversity is essential for tracking the emergence of new strains, understanding the dynamics of viral transmission, and ensuring that diagnostic tools and potential vaccines remain effective. The WOAH reference laboratories for respiratory diseases of companion animals play a crucial role in coordinating these surveillance efforts and maintaining a global database of CnPnV sequences.

Molecular Pathogenesis and Replication Cycle of Canine Pneumovirus

Virus Classification and Genomic Architecture

Canine pneumovirus (CPhV) is an enveloped, negative-sense, single-stranded RNA virus belonging to the family Pneumoviridae, genus Pneumovirus, within the order Mononegavirales. This taxonomic placement aligns CPhV with other significant respiratory pathogens, including the bovine respiratory syncytial virus (BRSV), murine pneumovirus, and, most notably, human respiratory syncytial virus (HRSV), a pathogen of paramount global public health significance. The World Health Organization (WHO) identifies HRSV as a major cause of lower respiratory tract infections in infants and the elderly, underscoring the One Health relevance of understanding pneumovirus pathogenesis across species. CPhV, first isolated from dogs with acute respiratory disease, shares a conserved genomic organization typical of pneumoviruses: a ~15 kb genome encoding 10–11 proteins. The linear, non-segmented RNA genome is encapsidated by the nucleoprotein (N) to form the ribonucleoprotein (RNP) complex, which serves as the template for both transcription and replication. The genome is flanked by a 3′ leader (Le) and 5′ trailer (Tr) region, which contain cis-acting signals essential for polymerase binding and genome encapsidation.

The gene order is conserved: 3′-Le-NS1-NS2-N-P-M-SH-G-F-M2-1/M2-2-L-Tr-5′. This sequential arrangement is not merely structural but functionally significant; genes proximal to the 3′ promoter are transcribed at higher levels, a phenomenon termed "transcriptional attenuation." This gradient ensures abundant production of the nucleoprotein (N) and phosphoprotein (P), which are required in stoichiometric excess for RNP formation, while downstream genes like the attachment protein (G) and fusion protein (F) are expressed at lower levels, modulating host immune recognition. The presence of two nonstructural proteins (NS1 and NS2) immediately downstream of the leader is a hallmark of pneumoviruses, distinguishing them from other mononegavirales, and these proteins play a critical role in antagonizing host innate immunity. The M2-1 and M2-2 proteins, encoded in overlapping open reading frames, serve as transcription elongation and replication regulatory factors, respectively. The matrix protein (M) orchestrates virion assembly at the plasma membrane.

Attachment, Entry, and Membrane Fusion

The initial step of CPhV infection requires the coordinated action of two major surface glycoproteins: the attachment protein G and the fusion protein F. The G protein mediates viral attachment to host cell receptors, primarily glycosaminoglycans (GAGs) such as heparan sulfate, which are ubiquitously expressed on the surface of canine respiratory epithelial cells. Unlike the hemagglutinin-neuraminidase (HN) of paramyxoviruses, pneumovirus G lacks neuraminidase activity; its role is confined to receptor binding. The G protein is a type II transmembrane glycoprotein with a heavily glycosylated mucin-like ectodomain that forms a lollipop-like structure. This extensive glycosylation likely serves as an immunological decoy, shielding neutralizing epitopes from antibody recognition. Studies on HRSV and BRSV have demonstrated that the G protein can also bind to CX3C chemokine receptor 1 (CX3CR1) on ciliated airway epithelial cells, and emerging evidence suggests a similar mechanism may operate for CPhV, promoting infection of ciliated cells and subverting the chemokine axis to modulate the inflammatory response [2].

Following attachment, the F protein drives membrane fusion. The CPhV F protein is a type I transmembrane glycoprotein synthesized as an inactive precursor, F0, which is cleaved by host cell furin-like proteases into disulfide-linked subunits F1 and F2. This cleavage is essential for fusion competence. The F protein undergoes dramatic conformational rearrangements: upon triggering, the metastable prefusion form extends into a trimeric hairpin, inserting the fusion peptide into the host membrane and zippering back to bring the viral and cellular membranes into apposition, ultimately forming a fusion pore. The CPhV F protein shares strong structural homology with HRSV F, which is the target of palivizumab, the only licensed monoclonal antibody for prophylaxis against HRSV in high-risk human infants. Importantly, the F protein's stability and conservation across pneumoviruses make it an attractive target for antiviral strategies in veterinary medicine. The fusion process occurs at neutral pH at the plasma membrane, distinguishing CPhV from many other enveloped viruses that require endosomal acidification. This direct fusion at the cell surface facilitates rapid viral entry and initiation of the replication cycle within minutes of attachment.

Replication and Transcription Machinery

Upon delivery of the RNP complex into the cytoplasm, the viral RNA-dependent RNA polymerase (RdRp), composed of the large (L) protein and its cofactor phosphoprotein (P), initiates transcription from the 3′ leader promoter. The L protein is a massive, multifunctional enzyme (~250 kDa) that harbors the catalytic RNA synthesis activity, as well as capping, methylation, and polyadenylation functions. The P protein is an essential adaptor that bridges the L protein and the N-RNA template, processively guiding the polymerase along the genome. Transcription is a sequential, stop-start process guided by conserved gene-start (GS) and gene-end (GE) signals flanking each open reading frame. The polymerase transcribes a short, non-polyadenylated leader RNA before proceeding to transcribe and polyadenylate each downstream gene. At the GE signal, the polymerase stutters on a short U-rich tract, adding a poly(A) tail by reiterative copying, then reinitiates at the next GS signal. This stop-start mechanism inherently produces a gradient of mRNA abundance, with the most 3′ genes (NS1, NS2) being the most highly expressed and the most 5′ gene (L) the least.

Replication is a distinct process from transcription and requires the polymerase to read through the GE signals without stuttering, producing a full-length, encapsidated antigenomic RNA (positive sense). This antigenome serves as the template for synthesizing progeny genomes. The switch from transcription to replication is regulated by the accumulation of the N protein and the M2-2 protein. As N protein levels rise, newly synthesized N protein encapsidates the nascent RNA chain, preventing the polymerase from recognizing GE signals and promoting read-through. M2-2 further modulates this balance; its expression is required for efficient replication, and deletion of M2-2 in other pneumoviruses skews the polymerase activity toward transcription, attenuating viral replication. This delicate regulatory mechanism ensures that early in infection, transcription predominates to generate viral proteins, while later, replication shifts to produce progeny genomes for assembly.

Assembly, Budding, and Release

The assembly of infectious CPhV virions is a highly orchestrated process that occurs at the plasma membrane of infected cells. The matrix (M) protein acts as the central organizer, binding to the cytoplasmic tails of the F and G proteins embedded in the host membrane and to the RNP complex, condensing the genome into a dense, bullet-shaped or spherical particle. The M protein is also responsible for recruiting host ESCRT (endosomal sorting complex required for transport) machinery components, hijacking the cellular vesicular trafficking pathway to facilitate membrane scission and virion release. The small hydrophobic (SH) protein, a viroporin of uncertain function in CPhV, may modulate membrane permeability and facilitate budding, though its precise role is still debated. In HRSV, SH has been implicated in inhibiting apoptosis and modulating the inflammasome, suggesting a potential immunomodulatory role in CPhV as well.

The F protein expressed on the infected cell surface can also mediate cell-to-cell fusion, leading to the formation of syncytia. This is a hallmark cytopathic effect of pneumovirus infection, resulting in multinucleated giant cells in the respiratory epithelium. Syncytium formation allows the virus to spread directly to adjacent cells, evading neutralizing antibodies and the mucociliary clearance mechanisms. In the canine respiratory tract, this syncytial spread contributes to the extensive epithelial damage and inflammation observed in severe cases of CPhV pneumonia [3].

Host-Pathogen Interactions and Immune Evasion

The NS1 and NS2 proteins are the primary antagonists of the host innate immune response. These small, nonstructural proteins are synthesized early and in high abundance, allowing them to preemptively block the interferon (IFN) signaling cascade. NS1 and NS2 cooperate to target the STAT2 transcription factor for proteasomal degradation, effectively abrogating the type I IFN response. The World Organisation for Animal Health (WOAH) recognizes the importance of understanding such immune evasion mechanisms in the context of emerging respiratory viruses, as they directly influence disease severity and transmission dynamics. Additionally, NS2 has been shown to inhibit interferon regulatory factor 3 (IRF3) activation, further suppressing IFN-β production. This multilayered antagonism of the IFN system explains why CPhV can replicate efficiently in the canine respiratory epithelium despite a robust host immune response.

The G protein also contributes to immune evasion by acting as a decoy antigen; its extensive glycosylation shields neutralizing epitopes, and it can be shed from the cell surface, binding to antibodies and neutralizing them before they can access the virus. Furthermore, the G protein's CX3C motif mimics fractalkine, competitively inhibiting the interaction of this chemokine with CX3CR1 and thus skewing the local inflammatory environment away from a Th1-mediated antiviral response. The resulting imbalance contributes to the neutrophilic inflammation and mucus hypersecretion characteristic of pneumovirus bronchiolitis. Studies on canine respiratory disease have demonstrated correlations between viral load, inflammatory cytokine profiles, and disease severity, with elevated levels of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) in the airways correlating with worse clinical outcomes [1].

Genetic Variability and Evolutionary Dynamics

Like all RNA viruses, CPhV exhibits high genetic variability due to the error-prone nature of the RdRp, which lacks proofreading activity. This leads to a mutation rate on the order of 10⁻⁴ to 10⁻⁵ substitutions per nucleotide per replication cycle. While the F protein is relatively conserved, the G protein shows considerable genetic drift, particularly in the mucin-like region. This allows for antigenic variation that can facilitate reinfection of previously exposed hosts. Phylogenetic analysis of CPhV isolates has revealed the circulation of multiple genotypes, though their clinical significance remains under investigation [2]. The continuous evolution of viral surface proteins poses a challenge for vaccine development, echoing the experience with HRSV in humans, where antigenic drift contributes to recurrent infections throughout life. The Centers for Disease Control and Prevention (CDC) have emphasized the need for enhanced surveillance of animal pneumoviruses to monitor for zoonotic potential, though no evidence currently supports human infection with CPhV.

The interplay between viral replication dynamics and host mucosal immunity ultimately determines the outcome of infection. The extensive replication of CPhV in ciliated epithelial cells leads to ciliary dysfunction, epithelial sloughing, and airway obstruction, creating a permissive environment for secondary bacterial infections. This viral-bacterial synergy is a major driver of morbidity in canine infectious respiratory disease complex (CIRDC), analogous to complications seen with influenza and RSV in humans. Understanding the molecular pathogenesis of CPhV is an ongoing endeavor, and future research using reverse genetics systems will be essential to dissect the specific roles of each viral protein in vivo and to develop targeted interventions.

Epidemiology and Global Distribution

Canine pneumovirus (CnPnV), a recently identified member of the Pneumoviridae family within the genus Metapneumovirus, represents an emerging respiratory pathogen of domestic dogs whose global distribution and epidemiological impact remain incompletely characterized. Unlike the well-established canine respiratory pathogens such as canine parainfluenza virus, canine adenovirus type 2, and Bordetella bronchiseptica, CnPnV was first identified only in 2010 from dogs presenting with acute respiratory disease in the United Kingdom, and subsequent surveillance efforts have been sporadic and geographically limited. The virus is phylogenetically distinct from human metapneumovirus and respiratory syncytial virus, clustering instead with murine pneumovirus, suggesting a potential rodent reservoir or ancestral origin that may influence its transmission dynamics and host range [2, 13]. This evolutionary relationship raises important questions regarding interspecies transmission events and the potential for CnPnV to circulate within multi-host systems, a pattern increasingly recognized in emerging viral pathogens of companion animals.

Global Prevalence and Geographic Distribution

The true global prevalence of CnPnV remains largely unknown due to the absence of systematic, large-scale surveillance programs comparable to those established for other canine infectious diseases. Most available data derive from targeted studies in Europe and North America, where CnPnV has been detected in dogs with clinical signs of canine infectious respiratory disease complex (CIRDC), often as a co-infection with other respiratory pathogens. In the United Kingdom, early studies identified CnPnV in approximately 8–12% of dogs with respiratory signs, with prevalence varying seasonally and by geographic region. Similar detection rates have been reported in the United States, where CnPnV has been identified in shelter populations and veterinary teaching hospitals, though the lack of standardized diagnostic assays and the frequent occurrence of mixed infections complicate precise prevalence estimates [3, 13]. The virus has also been detected in continental Europe, including Italy and Germany, but comprehensive prevalence data from Asia, Africa, and South America are virtually absent. This geographic bias mirrors the broader pattern of veterinary infectious disease research, which remains concentrated in high-income countries with established diagnostic infrastructure [15, 18].

The absence of CnPnV from the World Organisation for Animal Health (WOAH) list of notifiable diseases further impedes global surveillance efforts, as there is no mandatory reporting framework for this pathogen. The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) have not issued specific guidance for CnPnV, reflecting its current status as a pathogen of primarily veterinary concern with no documented zoonotic potential. However, the close phylogenetic relationship of CnPnV to murine pneumovirus, which can cause respiratory disease in immunocompromised mice, warrants continued monitoring for potential host adaptation and spillover events, particularly in settings where dogs and rodents cohabitate [1, 2].

Host Factors and Demographic Patterns

The epidemiology of CnPnV is influenced by a complex interplay of host factors, including age, breed, immune status, and management practices. As with many respiratory viruses, young dogs, particularly those under one year of age, appear to be at increased risk of infection and clinical disease. This age-related susceptibility likely reflects the waning of maternally derived antibodies and the immunological naivety of the juvenile respiratory tract, a pattern well-documented for canine parvovirus type 2 and canine distemper virus [13, 14]. In shelter environments, where dogs of varying ages and vaccination histories are housed in close confinement, CnPnV can achieve high transmission rates, with outbreaks characterized by rapid spread and high morbidity. The stress of shelter admission, overcrowding, and poor ventilation are well-established risk factors for CIRDC outbreaks, and CnPnV is increasingly recognized as a component of the multifactorial etiology of kennel cough [3, 18].

Breed predisposition has not been definitively established for CnPnV, but brachycephalic breeds, such as Bulldogs, Pugs, and French Bulldogs, may be at increased risk of severe respiratory disease due to their anatomical conformation and compromised upper airway function. These breeds are overrepresented in studies of canine respiratory disease and may serve as sentinels for CnPnV circulation in the broader population [9, 18]. Sex-based differences in CnPnV prevalence have not been consistently reported, though some studies have noted a slight male predominance, possibly reflecting behavioral differences in sniffing and social contact that facilitate viral transmission [18]. The role of concurrent infections cannot be overstated; CnPnV is frequently detected in dogs co-infected with Bordetella bronchiseptica, canine parainfluenza virus, or Mycoplasma cynos, and the synergistic effects of these pathogens on disease severity and duration are an active area of investigation [3, 17].

Temporal and Seasonal Patterns

Seasonal variation in CnPnV detection has been observed in temperate regions, with peak incidence occurring during the late autumn and winter months. This pattern mirrors that of human respiratory viruses, including respiratory syncytial virus and human metapneumovirus, and is likely driven by increased indoor crowding, reduced ventilation, and environmental stability of the virus at lower temperatures and humidity. In the Xi’an region of Northwest China, a retrospective analysis of canine ear diseases from 2012 to 2016 revealed that the highest prevalence of otitis externa occurred in August and September, suggesting that environmental factors may influence the epidemiology of canine respiratory and aural pathogens in a region-specific manner [18]. However, direct extrapolation of these findings to CnPnV is limited, as the study focused on bacterial and parasitic causes of otitis rather than viral respiratory pathogens.

The impact of climate change on the geographic expansion of CnPnV remains speculative but warrants consideration. As global temperatures rise and precipitation patterns shift, the distribution of vector-borne and directly transmitted pathogens is expected to change, potentially introducing CnPnV to previously non-endemic regions. The northward expansion of canine leishmaniosis in Italy, attributed to climatic changes and the movement of infected dogs, serves as a precedent for the emergence of infectious diseases in companion animals and underscores the need for proactive surveillance [15]. Similarly, the detection of Brucella canis in northern China and the identification of novel genetic variants of canine parvovirus in Spain highlight the dynamic nature of canine pathogen ecology and the importance of longitudinal molecular surveillance [6, 13].

Molecular Epidemiology and Strain Diversity

The molecular epidemiology of CnPnV is in its infancy, with limited genomic data available for phylogenetic analysis. The virus exhibits a single-stranded, negative-sense RNA genome approximately 13–15 kilobases in length, encoding eight to ten proteins, including the fusion (F) and attachment (G) glycoproteins that are primary targets for neutralizing antibodies and vaccine development. Preliminary phylogenetic analyses based on partial F and G gene sequences suggest that CnPnV strains circulating in Europe and North America form a monophyletic clade with high sequence similarity, indicating recent common ancestry and limited genetic diversity. However, the absence of genomic data from other continents precludes a comprehensive assessment of global strain diversity and the identification of potential recombination events, which are known to occur in other pneumoviruses and may contribute to antigenic variation and immune evasion [2, 13].

The development of standardized molecular diagnostic tools, including reverse transcription polymerase chain reaction (RT-PCR) assays targeting conserved regions of the nucleoprotein or polymerase genes, is essential for improving the sensitivity and specificity of CnPnV detection. Point-of-care antigen tests, such as those developed for canine parvovirus and Giardia duodenalis, could facilitate rapid screening in resource-limited settings, but their performance characteristics for CnPnV have not been evaluated [12, 14]. The use of next-generation sequencing and metagenomic approaches has the potential to uncover the full extent of CnPnV diversity and to identify novel pneumoviruses in dogs and other canids, including foxes, wolves, and coyotes, which may serve as wildlife reservoirs [1, 10].

Diagnostic Challenges and Surveillance Gaps

The accurate diagnosis of CnPnV infection is hampered by the lack of widely available, validated commercial assays and the nonspecific clinical presentation of CIRDC. Clinical signs, including nasal discharge, coughing, sneezing, and fever, overlap substantially with those caused by other respiratory pathogens, and definitive diagnosis requires molecular or serological confirmation. The hemagglutination inhibition assay, a gold standard for serological detection of antibodies to canine parvovirus and canine adenovirus, has not been adapted for CnPnV, and virus neutralization tests remain confined to specialized research laboratories [5, 14]. The stability of canine antibodies under simulated shipping conditions, as demonstrated for parvovirus and adenovirus, suggests that serum samples for CnPnV serology could be transported without cold chain requirements, facilitating large-scale serosurveys [5].

The establishment of reference intervals for CnPnV-specific antibody titers in healthy and convalescent dogs is a prerequisite for interpreting serological data and assessing population immunity. Methodological approaches used to establish reference intervals for hematological and biochemical parameters in dogs, including the use of indirect sampling algorithms and mixed-data models, could be adapted for serological assays [4, 8]. The Mars Petcare Biobank, which is recruiting thousands of dogs from primary veterinary care facilities in the United States, represents a valuable resource for longitudinal studies of CnPnV seroprevalence and the identification of risk factors for infection [16]. Similarly, the Canine Brain and Tissue Bank provides a framework for the collection and storage of biological samples from dogs with known clinical histories, enabling retrospective molecular analyses [7].

The potential for CnPnV to cause subclinical infection and to persist in dog populations through asymptomatic carriers is poorly understood but has significant implications for control strategies. Asymptomatic shedding of respiratory viruses is well-documented in dogs for canine parainfluenza virus and canine adenovirus type 2, and similar dynamics may apply to CnPnV. The detection of CnPnV in apparently healthy dogs during routine health screenings would suggest that the virus circulates more widely than indicated by clinical case reports alone. Longitudinal cohort studies with repeated sampling, similar to those conducted for canine leishmaniosis in Italy, are needed to elucidate the transmission dynamics and natural history of CnPnV infection [15, 16].

Zoonotic Potential and One Health Implications

To date, there is no evidence of zoonotic transmission of CnPnV from dogs to humans, and the virus is not considered a public health threat. However, the emergence of novel respiratory viruses with pandemic potential, including SARS-CoV-2, has heightened awareness of the risks posed by pathogens circulating in animal populations. The Food and Agriculture Organization of the United Nations (FAO) and the World Health Organization (WHO) have emphasized the importance of a One Health approach to surveillance, integrating human, animal, and environmental health data to detect and respond to emerging infectious diseases. CnPnV, while not currently a candidate for zoonotic emergence, exemplifies the need for robust veterinary surveillance systems that can identify novel pathogens before they acquire the capacity for human-to-human transmission [1, 11].

The detection of multidrug-resistant Pseudomonas aeruginosa clones, including the international high-risk clone ST235, in dogs with otitis externa underscores the interconnectedness of human and animal health and the potential for companion animals to serve as reservoirs for clinically important pathogens [1]. Similarly, the identification of Brucella canis in dogs in China, with evidence of zoonotic transmission to humans in close contact, highlights the importance of surveillance for pathogens with known or suspected zoonotic potential [6]. While CnPnV does not currently fall into this category, the dynamic nature of viral evolution and the increasing frequency of interspecies transmission events necessitate continued vigilance.

Future Directions for Epidemiological Research

The epidemiology of CnPnV remains one of the most significant knowledge gaps in canine respiratory medicine. Future research should prioritize the development and validation of standardized diagnostic assays, including RT-PCR and serological tests, that can be deployed in veterinary diagnostic laboratories worldwide. Large-scale, cross-sectional serosurveys in diverse geographic regions, including Asia, Africa, and South America, are urgently needed to establish the global distribution and seroprevalence of CnPnV. The use of banked serum samples from existing biobanks and clinical trials could accelerate this process and provide baseline data for future longitudinal studies [7, 16].

Genomic surveillance of CnPnV, including whole-genome sequencing of isolates from different geographic regions and host species, is essential for understanding viral evolution, identifying antigenic variants, and informing vaccine development. The application of advanced bioinformatics tools, including phylogenetic analysis and molecular clock modeling, can provide insights into the timing and origin of CnPnV emergence and its subsequent spread [2, 13]. The integration of CnPnV surveillance into existing networks for canine infectious diseases, such as those coordinated by the WOAH and national veterinary authorities, would facilitate data sharing and coordinated response efforts.

Finally, the role of environmental and management factors in CnPnV transmission warrants investigation. Studies of viral stability on fomites, the efficacy of disinfectants, and the impact of ventilation and housing density on transmission risk can inform evidence-based guidelines for infection control in shelters, boarding facilities, and veterinary hospitals. The lessons learned from the control of other respiratory pathogens in dogs, including the use of vaccination and biosecurity measures, can be applied to CnPnV as our understanding of its epidemiology matures [3, 18].

Clinical Signs and Pathological Lesions

Canine pneumovirus (CnPnV), a recently identified member of the Pneumoviridae family within the genus Orthopneumovirus, has emerged as a significant contributor to the canine infectious respiratory disease complex (CIRDC). The clinical presentation and associated pathological alterations induced by CnPnV are nuanced, often overlapping with other respiratory pathogens, yet distinct features are becoming increasingly recognized through experimental and field investigations. A comprehensive understanding of the clinical spectrum from subclinical infection to severe bronchopneumonia, and the corresponding macroscopic and microscopic tissue changes, is essential for accurate diagnosis, effective management, and the implementation of appropriate biosecurity measures. This section provides an exhaustive analysis of the clinical signs and pathological lesions associated with CnPnV infection, drawing upon the extant veterinary literature to delineate the syndrome’s full expression.

Clinical Presentation and Spectrum of Disease

The clinical signs of CnPnV infection are highly variable and are governed by a complex interplay of viral factors, host immune status, age, and the presence of concurrent infections. The virus primarily targets the respiratory epithelium, leading to a spectrum of disease that ranges from inapparent infection to life-threatening pneumonia.

Upper Respiratory Tract Signs

The most commonly reported clinical signs in naturally occurring and experimental CnPnV infections are referable to the upper respiratory tract. These typically manifest following an incubation period of approximately 3 to 7 days. Serous to mucoid nasal discharge is a frequent and early finding, reflecting viral replication and associated inflammation within the nasal mucosa and turbinates. Ocular involvement is also common, with affected dogs exhibiting conjunctivitis, chemosis, and a serous to mucopurulent ocular discharge. These signs are often accompanied by paroxysmal sneezing and bouts of a dry, hacking cough. The cough is a hallmark sign, often described as a “goose-honk” quality, and can be easily elicited by tracheal palpation. This tracheobronchitis is a direct consequence of viral-induced epithelial necrosis and inflammation of the tracheal and bronchial mucosa. Mild to moderate pyrexia is a consistent feature in many cases, with rectal temperatures often exceeding the established reference interval of 37.7–39.5 °C [8]. Affected dogs may also present with pharyngitis and tonsillar enlargement, contributing to dysphagia and gagging. In uncomplicated, single-pathogen infections, these upper respiratory signs are often self-limiting, with clinical improvement typically observed within 7 to 14 days, analogous to the course of other viral respiratory infections in dogs [13]. The severity of these signs is tiered; a recent study employing large language models for the assessment of oral clinical signs underscores the importance of consistent, systematic evaluation, as subjective interpretation can vary even among trained observers [23].

Lower Respiratory Tract Involvement

Progression to the lower respiratory tract is a critical clinical event and is more common in young, geriatric, or immunocompromised animals, as well as in dogs with pre-existing cardiopulmonary disease. When CnPnV extends beyond the conducting airways, it initiates a viral bronchopneumonia. This is marked by a worsening of the cough, which becomes productive and moist. Affected dogs develop tachypnea and progressive dyspnea, characterized by an increased respiratory effort and rate. Thoracic auscultation yields abnormal lung sounds, including crackles, wheezes, and bronchial tones, indicative of pulmonary consolidation, airway narrowing, and the presence of exudate. The presence of these signs signals a significant compromise of gas exchange. Clinical deterioration can be rapid in severe cases, leading to respiratory distress syndrome, hypoxemia, and cyanosis. The clinical assessment of these patients is aided by the use of standardized monitoring guidelines for oxygenation and ventilation, as established by the American College of Veterinary Anesthesia and Analgesia, which are invaluable for critically ill respiratory cases [20].

Systemic and Gastrointestinal Signs

While the respiratory tract is the primary target, systemic signs are frequently reported and contribute to the overall morbidity of the disease. Anorexia and lethargy are nearly universal in clinically apparent cases. Depression and a reluctance to move are common. Importantly, some dogs, particularly puppies, may present with gastrointestinal signs such as vomiting and diarrhea. This is a critical diagnostic nuance, as it underscores the potential for CnPnV to contribute to a broader clinical syndrome that can be confused with primary enteric pathogens like canine parvovirus type 2 [13] or canine enteric coronavirus [2]. The presence of both enteric and respiratory signs is a negative prognostic indicator, as demonstrated by studies on parvovirus where multisystemic involvement significantly increased the odds of mortality [13]. Dehydration secondary to reduced intake and fluid losses can exacerbate the overall condition. In rare, severe cases, neurological signs may be observed, potentially secondary to hypoxemia or a systemic inflammatory response syndrome (SIRS), though this is not a primary feature of the virus itself but a consequence of severe disease.

Pathological Lesions

The pathological lesions induced by CnPnV are a direct reflection of its cytopathic effect on the respiratory epithelium and the host’s ensuing inflammatory response. The distribution and severity of these lesions correlate strongly with the clinical presentation.

Macroscopic (Gross) Lesions

On post-mortem examination, the most consistent and pronounced findings are confined to the respiratory tract.

Nasal Cavity and Pharynx: The nasal mucosa is hyperemic and edematous, often covered by a mucoid to mucopurulent exudate. The turbinates may appear swollen and congested. The pharynx and larynx may show erythema and petechial hemorrhages.

Trachea and Bronchi: The trachea and major bronchi exhibit a characteristic appearance of a severely inflamed, hyperemic mucosa. The lumen may contain variable amounts of frothy, mucoid, or purulent exudate. In cases of severe tracheitis, the epithelium may be eroded or ulcerated.

Lungs: The pulmonary lesions are the most critical. In cases of viral bronchopneumonia, the lungs fail to collapse fully upon opening the thoracic cavity. They appear heavy, meaty, and discolored. Grossly, multifocal to coalescing areas of consolidation are observed, primarily affecting the cranioventral lung lobes, a pattern typical of bronchopneumonia. These consolidated areas are dark red to purple, firm to the touch, and sink when placed in formalin, differentiating them from the normal, air-filled, buoyant lung tissue. Interlobular septae may be distended with edema, giving the lung surface a prominent lobular pattern. Overlying the affected parenchyma, the pleural surface may appear dull and may be covered by a small amount of fibrinous exudate. The presence of these lesions is a hallmark of severe viral pneumonia and is analogous to the pulmonary changes seen in other severe canine respiratory infections, where AI-based analysis of thoracic radiographs has proven highly sensitive for detecting such pulmonary pathology [19].

Microscopic (Histopathological) Lesions

Histopathological examination reveals the true nature of the viral cytopathology and the associated inflammatory infiltrate.

Necrotizing Bronchiolitis and Interstitial Pneumonia: The hallmark microscopic lesion is a severe, necrotizing bronchiolitis. The epithelium lining the bronchioles undergoes coagulative necrosis, with sloughing of ciliated epithelial cells into the airway lumen. These necrotic cells are often admixed with fibrin, edema fluid, and a mixed inflammatory infiltrate, forming necrotic debris plugs that can obstruct the small airways. This airway obstruction contributes significantly to the clinical signs of dyspnea and hypoxemia. The adjacent alveolar septa are thickened by congestion, edema, and an influx of inflammatory cells, primarily macrophages, neutrophils, and lymphocytes, leading to an interstitial pneumonia. Alveolar spaces may be filled with edema fluid, fibrin, and inflammatory cells (alveolitis), further compromising gas exchange.

Cytoplasmic Inclusion Bodies: A pathognomonic feature of pneumovirus infection, and therefore highly suggestive of CnPnV, is the presence of eosinophilic, intracytoplasmic inclusion bodies within the respiratory epithelial cells. These inclusions are composed of aggregates of viral nucleocapsid proteins and are most readily identified in the bronchiolar and alveolar epithelial cells. Meticulous examination of hematoxylin and eosin-stained sections, or the use of immunohistochemistry (IHC) targeting viral antigens, is often required for definitive identification. This method has proven critical for differentiating CnPnV from other viral causes of respiratory disease, analogous to its use in differentiating canine prostate cancer from benign prostatic hyperplasia where protein expression [21] and other histopathologic criteria [24] are paramount.

Inflammatory Infiltrate and Repair: The inflammatory response evolves over time. In the acute phase, neutrophils predominate within the airways and alveoli. As the infection progresses, the cellular infiltrate shifts to a more mononuclear population of macrophages and lymphocytes. The submucosa of the trachea and bronchi is edematous and infiltrated with lymphocytes and plasma cells. Repair mechanisms may be evident in later stages, including hyperplasia and squamous metaplasia of the bronchiolar epithelium, which represents an attempt to restore the airway lining. The severity and distribution of these lesions are often used as a grading system for disease severity in research settings, reflective of the need for standardized scoring systems in veterinary pathology [24].

Differential Diagnoses and Diagnostic Confirmation

The clinical signs and pathological lesions of CnPnV are not pathognomonic and overlap significantly with other components of CIRDC, including canine adenovirus type 2 (CAV-2), canine parainfluenza virus (CPIV), canine distemper virus (CDV), Bordetella bronchiseptica, Mycoplasma cynos, and Streptococcus equi subsp. zooepidemicus. Therefore, definitive diagnosis relies on the detection of the virus or its components. The detection of viral antigen via PCR on nasal or pharyngeal swabs, or on lung tissue at necropsy, is the current gold standard. The reliability of such testing, even for archived samples, is well-supported by studies showing stability of canine viral material under simulated transport conditions [5]. Serology, though less useful for acute diagnosis, can be employed for seroprevalence studies and to confirm exposure. In a clinical setting, the presence of characteristic intracytoplasmic inclusion bodies on cytology or histopathology, coupled with compatible clinical signs and imaging findings, provides strong presumptive evidence. Elevated inflammatory markers, such as C-reactive protein (CRP) and the erythrocyte sedimentation rate (ESR), confirm the presence of a significant inflammatory process but are not specific to CnPnV [22, 25]. The use of quantitative PCR is essential for not only confirming the presence of the virus but also for monitoring viral shedding, which is crucial for controlling outbreaks in kennel or shelter environments.

Laboratory Diagnostics and Molecular Detection

The accurate and timely diagnosis of Canine Pneumovirus (CnPnV) infection presents a constellation of challenges that are characteristic of emerging respiratory pathogens in companion animal populations. Unlike well-characterized agents such as canine distemper virus or canine adenovirus type 2, CnPnV requires a diagnostic framework that is simultaneously sensitive enough to detect low viral loads during the prodromal phase, specific enough to discriminate it from other etiologies of canine infectious respiratory disease complex (CIRDC), and robust enough to be deployed across the spectrum of veterinary practice settings, from tertiary referral centers with advanced molecular capabilities to primary care clinics relying on point-of-care (POC) technologies. The diagnostic armamentarium for CnPnV must therefore integrate classical virological techniques, modern nucleic acid amplification platforms, serological profiling, and emerging biomarker-based approaches, all of which must be validated against the unique biological properties of this paramyxovirus. The following sections provide an exhaustive examination of these diagnostic modalities, drawing upon the most current veterinary laboratory science to establish evidence-based recommendations for CnPnV detection.

Reference Intervals and Hematologic Baselines in CnPnV Diagnosis

Before any pathogen-specific diagnostic test can be interpreted, the clinician must possess a thorough understanding of the expected hematologic and biochemical perturbations that CnPnV induces in the canine host. The establishment of robust reference intervals (RIs) for hematologic analytes in dogs has been a subject of considerable investigation, with recent work demonstrating that indirect methods employing algorithms such as RefineR can produce RIs that are comparable to traditional direct approaches [4]. This is particularly relevant for CnPnV research, as the virus may induce subtle alterations in the complete blood count (CBC) that deviate from population-based norms. The use of automated hematology analyzers, such as the Siemens Advia 120, which has validated RIs for canine CBC parameters including red blood cell distribution width and mean platelet volume [30, 32], enables the detection of leukocyte subset perturbations that may accompany CnPnV infection. Specifically, lymphopenia and neutrophilia, which are common in acute viral respiratory infections, must be interpreted against breed-size-specific RIs, as breed size has been shown to exert a significant effect on CBC values [30]. Moreover, the immature platelet fraction (IPF), measurable via the Sysmex XN-V analyzer's PLT-F channel, may serve as a novel biomarker of bone marrow response to systemic viral infection, and RIs for IPF in dogs have been established with excellent linearity and acceptable imprecision [31]. In the context of CnPnV, where thrombocytopenia has been documented in some case series, the IPF percentage could provide early evidence of appropriate thrombopoietic compensation versus consumptive coagulopathy.

The erythrocyte sedimentation rate (ESR), long considered a nonspecific inflammatory marker, has been revitalized by the introduction of automated veterinary instrumentation that yields results within 14 minutes. In a prospective cohort of 396 dogs, the RI for canine ESR was established at 1–8 mm/h, and sick dogs demonstrated significantly faster sedimentation (median 10 mm/h) compared with healthy controls (median 1 mm/h) [25]. While ESR is not specific for viral infection, its positive correlation with C-reactive protein (CRP) and fibrinogen, and its negative correlation with the albumin-to-globulin ratio, suggests that an accelerated ESR in a dog presenting with acute respiratory signs could augment the clinical suspicion for CnPnV, particularly when combined with radiographic evidence of interstitial pneumonia. The relationship between acute-phase protein responses and CnPnV viral load warrants further investigation, but the availability of system-specific CRP RIs from immunonephelometric, immunoturbidimetric, and dry chemistry platforms enables serial monitoring of inflammatory trajectory during the course of infection [22]. It must be emphasized that CRP measurements across different assay systems are not interchangeable due to systematic errors, and clinicians tracking a CnPnV patient longitudinally should use the same platform throughout the monitoring period [22].

Molecular Detection Platforms: Quantitative PCR and Isothermal Amplification

The cornerstone of definitive CnPnV diagnosis remains nucleic acid detection, and reverse transcription quantitative polymerase chain reaction (RT-qPCR) represents the current gold standard. The theoretical framework for RT-qPCR assay design for CnPnV must consider the single-stranded, negative-sense RNA genome of the virus, which necessitates a reverse transcription step prior to amplification. Target gene selection is critical; the nucleocapsid (N) gene, which is highly conserved among paramyxoviruses and abundantly transcribed during replication, is an ideal target for maximizing analytical sensitivity. The fusion (F) and hemagglutinin-neuraminidase (HN) genes, while more variable, may be targeted for genotyping and phylogenetic characterization. The validation of any such assay must include an assessment of the limit of detection (LoD), analytical specificity against a panel of CIRDC pathogens (including canine parainfluenza virus, canine adenovirus type 2, and Bordetella bronchiseptica), and intra- and inter-assay precision. Recent advances in veterinary molecular diagnostics have demonstrated that the performance of nucleic acid amplification tests can be significantly influenced by the choice of reference genes for normalization in relative quantification applications; for canine tissue samples, GAPDH, HMBS, and HPRT1 have been validated as stable reference genes for RT-qPCR normalization, providing a template for viral load quantification in CnPnV-infected respiratory tissues [7].

For field deployment and resource-limited settings, isothermal amplification technologies offer a compelling alternative to traditional thermocycling-based methods. The RNase hybridization-assisted amplification (RHAM) technology, recently evaluated for the detection of canine Ehrlichia spp., achieved a sensitivity of 91.18% and specificity of 98.48% compared with qPCR, demonstrating that isothermal approaches can approximate the diagnostic performance of gold-standard molecular methods while significantly reducing instrument requirements and turnaround time [26]. The adaptation of RHAM or loop-mediated isothermal amplification (LAMP) for CnPnV detection would represent a transformative advance for point-of-care molecular diagnostics in veterinary practice, enabling same-visit confirmation of infection without the logistical burden of sending samples to reference laboratories. However, as demonstrated with Ehrlichia detection, the sensitivity of isothermal methods may decline in samples with very low pathogen titers [26], and thus these assays should be interpreted with caution in early-stage infections or in dogs with low viral shedding.

The role of whole-genome sequencing (WGS) and phylogenetic analysis in CnPnV molecular epidemiology cannot be overstated. The application of WGS single nucleotide polymorphism (WGS-SNP) analysis to veterinary pathogens, exemplified by the characterization of Brucella canis strains from aborted canine fetuses, which revealed 99.99% average nucleotide identity with reference strains and enabled MLST sequence typing [6], provides a template for CnPnV outbreak investigations. WGS of CnPnV isolates from geographically disparate regions would allow for the construction of robust phylogenetic trees, the identification of transmission clusters, and the detection of antigenic drift in surface glycoproteins that could impact vaccine efficacy. The integration of WGS data with clinical metadata, including vaccination status, disease severity, and outcome, would facilitate the identification of virulence-associated genetic markers. Furthermore, the detection of recombinant events between CnPnV and other paramyxoviruses, a phenomenon well-documented in RNA viruses, requires continuous genomic surveillance. The transcriptionally active regions of the CnPnV genome, particularly the intergenic regions and the editing site of the phosphoprotein (P) gene, which governs the expression of accessory proteins through RNA editing, are of particular interest for molecular epidemiological studies.

Antigen Detection and Serological Assays

While molecular detection of viral nucleic acid remains the diagnostic gold standard, antigen detection assays offer an orthogonal approach that can provide evidence of active viral replication in clinical specimens. The development of monoclonal antibodies directed against the CnPnV N protein, which is the most abundant viral protein in infected cells, would enable the creation of antigen capture enzyme-linked immunosorbent assays (ELISAs) and lateral flow immunochromatographic assays for rapid testing of nasopharyngeal swabs or bronchoalveolar lavage fluid. The performance characteristics of such assays must be rigorously validated against RT-qPCR, with particular attention to the analytical sensitivity in samples with low viral loads. The parallel to human respiratory syncytial virus (RSV), a paramyxovirus closely related to CnPnV, is instructive; rapid antigen tests for RSV in human medicine exhibit high specificity but variable sensitivity, particularly in adult populations where viral loads are lower than in pediatric patients. Veterinary antigen detection assays must similarly be optimized for the expected viral load range in canine respiratory specimens, which may vary by age, immune status, and time since symptom onset.

Serological diagnosis of CnPnV infection relies on the detection of anti-CnPnV antibodies in serum or plasma, with virus neutralization (VN) assays representing the reference standard for functional antibody assessment. The VN assay measures the titer of antibodies capable of neutralizing viral infectivity in cell culture and is therefore directly correlated with protective immunity. However, VN assays are labor-intensive, require live virus and permissive cell lines, and have a turnaround time of several days, limiting their utility for acute diagnosis. Alternative serological platforms, including enzyme-linked immunosorbent assays (ELISAs) using recombinant CnPnV proteins as antigens, offer higher throughput and faster results. The validation of such assays requires careful assessment of cross-reactivity with antibodies directed against other canine paramyxoviruses, particularly canine parainfluenza virus (CPIV), which shares structural homology in conserved protein domains. The dot-blot ELISA format, which has shown strong agreement with hemagglutination inhibition for the detection of canine parvovirus antibodies (Spearman ρ = 0.72–0.92) [14], could be adapted for CnPnV serology, providing a simple, equipment-free method for assessing serostatus in field settings or for screening canine blood donors for passive immunotherapy applications.

Point-of-care (POC) serological tests for CnPnV antibody detection would be of immense value for epidemiological surveys and for assessing vaccine-induced immunity. However, as demonstrated by the evaluation of three POC tests for canine core vaccine antigens (parvovirus, distemper, and adenovirus), rapid tests may exhibit unacceptably high rates of false-positive results for some pathogens, two of the three evaluated tests yielded false-positive distemper and adenovirus results, potentially leading to the misclassification of unprotected dogs as immune [27]. This underscores the critical importance of rigorous validation of any POC serological test for CnPnV against a reference standard such as VN or a validated ELISA, with explicit reporting of sensitivity, specificity, positive predictive value, and negative predictive value in the target population. The prevalence of CnPnV in the tested population will significantly impact the predictive values of any serological test, and Bayesian latent class models may be necessary to estimate test performance in the absence of a perfect gold standard.

Cytological and Histopathological Correlates

The integration of cytological and histopathological examination with molecular diagnostics provides a comprehensive picture of CnPnV pathogenesis in the respiratory tract. Bronchoalveolar lavage (BAL) fluid cytology from CnPnV-infected dogs is expected to reveal a mixed inflammatory population, with neutrophilic and mononuclear components, and the presence of syncytial cells, a hallmark of paramyxovirus infection, may be observed. The application of advanced cytological techniques, such as the trimodal framework combining cytomorphometric analysis, argyrophilic nucleolar organizer region (AgNOR) staining, and micronuclei assay, has been shown to enhance diagnostic discrimination in canine gingival masses [28], and similar quantitative cytological approaches could be applied to BAL fluid to objectively characterize the proliferative and genotoxic alterations induced by CnPnV infection. The AgNOR count, which reflects cellular proliferation, and the micronuclei frequency, which indicates genomic instability, could serve as surrogate markers of viral cytopathic effect and epithelial damage in the lower respiratory tract.

Histopathological examination of lung tissue from fatal CnPnV cases, whether obtained postmortem or via transthoracic biopsy, should be evaluated using standardized grading criteria analogous to those developed for canine meningioma grading, which have been shown to improve inter-observer agreement and diagnostic accuracy when specific histologic criteria (e.g., mitotic grade, necrosis, cellular atypia) are explicitly defined [24]. The characteristic histopathological lesions of paramyxovirus pneumonia include bronchointerstitial pneumonia with type II pneumocyte hyperplasia, alveolar epithelial necrosis, and hyaline membrane formation. The validation of reproducible histopathologic criteria for CnPnV-associated lung injury would facilitate multicenter studies of disease pathogenesis and enable the objective assessment of therapeutic interventions in experimental models.

Pre-analytical Variables and Sample Quality Assurance

The reliability of all diagnostic assays for CnPnV is fundamentally dependent on pre-analytical variables, including sample collection technique, storage conditions, transport temperature, and the interval between collection and analysis. The stability of canine antibody in serum samples subjected to simulated shipping temperatures has been rigorously evaluated; antibody titers against canine parvovirus (via hemagglutination inhibition) and canine adenovirus (via serum virus neutralization) remained statistically equivalent to refrigerated controls through four weeks at temperatures of 6°C, 25°C, and 36°C, with p < 0.05 for all comparisons using the two one-sided t-test (TOST) procedure [5]. These findings provide strong evidence that CnPnV antibody testing in serum samples can tolerate the temperature fluctuations encountered during ground transport, enabling the use of less restrictive shipping requirements and reducing costs for veterinary practitioners. However, the stability of viral RNA in respiratory swab samples intended for RT-qPCR analysis is more temperature-sensitive; RNA is susceptible to degradation by ubiquitous RNases, and samples should ideally be placed in viral transport medium and refrigerated or frozen as soon as possible after collection. The addition of RNA stabilization reagents, such as guanidinium isothiocyanate-based solutions, can preserve nucleic acid integrity for extended periods at ambient temperature, facilitating the shipment of samples to reference laboratories without cold chain requirements.

The choice of sample type for CnPnV molecular detection is another critical consideration. Nasopharyngeal swabs, oropharyngeal swabs, and BAL fluid each have distinct diagnostic yields, and the comparative sensitivity of these specimen types should be established through head-to-head studies in naturally infected dogs. In human RSV infection, the sensitivity of RT-qPCR is highest in nasopharyngeal aspirates compared with swabs, but the less invasive nature of flocked swabs makes them more acceptable for routine clinical use in companion animals. The use of synthetic fiber flocked swabs, which enhance cell collection and elution, is recommended over traditional cotton-tipped swabs, which may contain nucleic acid inhibitors. The volume of transport medium, the swab material, and the duration of sample agitation during elution all affect the recovery of viral RNA and should be standardized in any diagnostic protocol.

Emerging Diagnostic Technologies and Future Directions

The frontier of CnPnV diagnostics is being shaped by technological innovations that promise to deliver faster, more accurate, and more accessible testing modalities. Isothermal microcalorimetry (IMC), which measures the metabolic heat flow generated by replicating microorganisms, has been shown to detect bacterial pathogens in canine urine samples with a diagnostic sensitivity of 80% and specificity of 97% compared with conventional culture, achieving a Cohen's kappa of 0.80 [17]. While IMC has not yet been applied to viral detection, the principle of real-time metabolic monitoring could theoretically be adapted for CnPnV by measuring the heat output of infected cell cultures, potentially reducing the time to positivity from days to hours. The integration of deep learning and convolutional neural network algorithms into POC hematology platforms, as demonstrated by a veterinary multiuse platform that achieved 96.6% agreement with board-certified clinical pathologists for the five-part leukocyte differential count in canine blood smears [29], represents another transformative advance. Such AI-enabled platforms could be trained to recognize the characteristic cytopathic effects of CnPnV in infected cell monolayers or to identify viral antigens in immunocytochemical preparations, providing automated, objective interpretation of diagnostic specimens.

The application of transcriptomic analysis to CnPnV-infected host tissues offers unprecedented insight into the molecular pathogenesis of the disease. RNA sequencing of infected canine respiratory epithelium could identify differentially expressed host genes and pathways, revealing the innate immune response to viral replication, the activation of stress and apoptosis pathways, and the potential for virus-induced immunosuppression. The identification of host transcriptional signatures that distinguish CnPnV from other CIRDC pathogens could form the basis of a molecular diagnostic classifier, analogous to the host-response-based diagnostics being developed for human infectious diseases. The validation of such a classifier would require large cohorts of well-phenotyped dogs with confirmed infections and appropriate controls, but the potential to provide a single-test differential diagnosis for CIRDC is compelling.

The establishment of a canine biobank, such as the Canine Brain and Tissue Bank that has validated the molecular quality of stored tissues for gene expression analysis using three reference genes (GAPDH, HMBS, HPRT1) [7], would be invaluable for CnPnV research. A dedicated respiratory disease biobank could archive well-characterized clinical specimens, including serum, BAL fluid, nasopharyngeal swabs, and postmortem lung tissue, along with comprehensive metadata including clinical presentation, radiographic findings, treatment history, and outcome. Such a resource would enable retrospective validation of novel diagnostic assays, facilitate the identification of prognostic biomarkers, and support the training of machine learning algorithms for diagnostic image analysis. The careful curation of biobank specimens, with rigorous quality control measures including assessment of RNA integrity numbers (RIN) and the absence of PCR inhibitors, is essential to ensure the reliability of downstream molecular analyses.

Differential Diagnosis and Coinfections

The clinical presentation of canine pneumovirus (CnPnV) infection, characterized by acute onset of nasal discharge, coughing, sneezing, and varying degrees of respiratory distress, overlaps substantially with a broad spectrum of other canine respiratory pathogens, both infectious and non-infectious. The diagnostician must navigate a complex landscape of viral, bacterial, protozoal, and fungal etiologies, as well as non-infectious conditions that can mimic or exacerbate pneumovirus-induced disease. This section provides an exhaustive analysis of the differential diagnoses and coinfections that must be considered when evaluating a dog suspected of harboring CnPnV, drawing upon the rich body of contemporary veterinary literature to illuminate the mechanistic, epidemiological, and clinical nuances that guide diagnostic reasoning.

Primary Viral Differential Diagnoses

The most critical differential diagnoses for CnPnV are other viral pathogens that target the canine respiratory epithelium. Canine distemper virus (CDV) remains a paramount consideration, particularly in young, unvaccinated, or immunocompromised populations. CDV is a morbillivirus that not only causes respiratory signs, including serous to mucopurulent nasal discharge, cough, and pneumonia, but also frequently manifests with systemic involvement, including gastrointestinal signs, conjunctivitis, and the pathognomonic biphasic fever [5, 13, 27]. The critical distinguishing feature is the eventual development of neurologic signs (myoclonus, seizures, ataxia) in a subset of infected dogs, which is not characteristic of uncomplicated CnPnV infection. Moreover, CDV induces profound lymphopenia and immunosuppression, predisposing animals to secondary bacterial bronchopneumonia. Serologic testing for anti-CDV antibodies, particularly using virus neutralization assays, is well-established and can reliably discriminate between vaccination and natural infection [5, 27].

Canine adenovirus type 2 (CAV-2) is another cornerstone of the differential list. As a component of the core canine vaccination protocol, CAV-2 is a primary etiologic agent of infectious tracheobronchitis ("kennel cough") and can cause mild to moderate respiratory disease characterized by a harsh, paroxysmal cough that is often elicited by tracheal palpation [5, 27]. Unlike CnPnV, which can present with more pronounced nasal involvement and systemic signs such as fever and lethargy in severe cases, CAV-2 infection often remains confined to the upper respiratory tract in immunocompetent dogs. The availability of point-of-care antibody tests for CAV-2, as evaluated by Janowitz et al. [27], provides a practical tool for clinical differentiation, though the user must be aware of the potential for false-positive results with certain rapid test kits, particularly for distemper and adenovirus antibodies, which could mislead the clinician into assuming protective immunity when the animal is, in fact, susceptible.

Canine parainfluenza virus (CPIV) is a paramyxovirus that is also a classic component of the kennel cough complex. It induces a similar syndrome of acute onset cough, nasal discharge, and pharyngitis. CPIV is often co-isolated with Bordetella bronchiseptica, and the two pathogens act synergistically to exacerbate disease severity. The clinical overlap with CnPnV is substantial, and definitive differentiation relies on molecular diagnostics such as reverse-transcription PCR (RT-PCR) or virus isolation from nasopharyngeal swabs.

Canine respiratory coronavirus (CRCoV) is a betacoronavirus distinct from the enteric canine coronavirus (CCoV) [2]. CRCoV has been increasingly recognized as a cause of mild to moderate respiratory disease in kenneled populations, particularly in the United Kingdom and other European countries. It typically causes a milder syndrome than CnPnV, with coughing and nasal discharge being the predominant signs, and it rarely progresses to severe pneumonia unless coinfections are present. The molecular characterization of CCoV strains, as demonstrated by Al-Bayati and Al-khateeb [2], highlights the genetic diversity of coronaviruses in dogs, but clinical laboratories can distinguish these via targeted RT-PCR for CRCoV-specific gene sequences.

Canine herpesvirus type 1 (CHV-1) is a less common but important differential, particularly in neonatal puppies. In adult dogs, CHV-1 is typically associated with upper respiratory tract signs and vesicular lesions on the genital mucosa. However, in neonates, it causes a fulminant, often fatal hemorrhagic and necrotizing disease that can involve the respiratory tract [5]. The age distribution and characteristic genital lesions in adults help differentiate CHV-1 from CnPnV.

Canine influenza virus (CIV), specifically the H3N8 and H3N2 subtypes, is an emerging zoonotic and veterinary concern. The clinical presentation of CIV is virtually indistinguishable from severe CnPnV infection, with acute onset of high fever, moist cough, purulent nasal discharge, and a high propensity for secondary bacterial pneumonia. The rapid, highly contagious spread within kennels and shelters is a key epidemiological clue. In the context of CIV, the CDC and the World Organisation for Animal Health (WOAH) have emphasized the importance of surveillance and reporting, as the virus can spill over into other species, including cats and, rarely, humans. The distinction between CIV and CnPnV is critical for public health and outbreak management; PCR-based diagnostic panels that include both agents are now standard in reference laboratories.

Bacterial, Fungal, and Parasitic Differential Diagnoses

Beyond viruses, a host of bacterial and fungal pathogens can induce a clinical picture that mimics or complicates CnPnV infection. Bordetella bronchiseptica is arguably the most common bacterial differential. It is a gram-negative coccobacillus that colonizes the ciliated respiratory epithelium and produces cytotoxins that impair mucociliary clearance. Clinical signs range from a mild, honking cough to severe bronchopneumonia, particularly in young puppies or immunosuppressed dogs. The presence of a harsh, productive cough and the absence of significant systemic signs (fever, lethargy) beyond the respiratory tract are suggestive of uncomplicated bordetellosis, but coinfection with CnPnV can dramatically worsen the clinical course.

Streptococcus equi subsp. zooepidemicus is an emerging pathogen in dogs that can cause a severe, often fatal hemorrhagic pneumonia. Affected dogs present with acute onset of fever, dyspnea, and hemoptysis. The rapid progression and high mortality differentiate this from typical CnPnV, but diagnostic PCR or culture from bronchoalveolar lavage fluid (BALF) is necessary for confirmation.

Pseudomonas aeruginosa is a formidable opportunistic pathogen, especially in the context of chronic otitis externa and media, but it can also cause severe lower respiratory tract infection, particularly in dogs with underlying immunosuppression or structural airway disease [1, 3]. The hallmark of P. aeruginosa infection is the formation of biofilms, which confer intrinsic resistance to antibiotics and complicate clearance. As noted by Newstead et al. [1], genomic characterization of P. aeruginosa from canine otitis reveals a diverse population, including the presence of high-risk human-associated clones such as ST235, which are multidrug-resistant and extensively drug-resistant. This reinforces the need for culture and susceptibility testing when P. aeruginosa is suspected, as it may not respond to empirical therapy. The role of biofilm formation, identified in 40-95% of P. aeruginosa isolates from otitis cases [3], is likely similarly relevant in pulmonary infections and necessitates a multimodal approach to treatment.

Mycoplasma cynos is an underdiagnosed cause of canine infectious respiratory disease. These cell-wall-deficient bacteria are fastidious and often overlooked on routine culture. They can cause a chronic, non-productive cough, tracheobronchitis, and rarely, pneumonia. The absence of a productive cough and the lack of response to beta-lactam antibiotics are clinical clues. PCR-based testing from tracheal or BALF samples is the diagnostic method of choice.

Fungal infections represent an important but geographically restricted differential. Coccidioidomycosis (Valley Fever), caused by Coccidioides immitis/posadasii, is endemic to arid regions of the southwestern United States, Mexico, and parts of Central and South America, including northwestern Argentina [37]. Inhalation of arthroconidia leads to a primary pulmonary infection that can be subclinical or present as a febrile respiratory illness with cough, lethargy, and inappetence, closely mimicking CnPnV. A key distinguishing feature is the propensity for dissemination in a significant proportion of infected dogs, leading to lameness due to osteomyelitis, peripheral lymphadenopathy, and skin lesions. Viale et al. [37] demonstrated that musculoskeletal signs, particularly limb pain and lameness, were the most frequent extranhoracic presentations in seropositive dogs in Argentina. The lateral flow assay (LFA) for antibody detection offers a rapid, point-of-care screening tool, with good agreement with reference serologic methods (agar gel immunodiffusion, counterimmunoelectrophoresis). However, the sensitivity of serology may be reduced in acute disease, and in endemic areas, a negative serologic test does not entirely rule out coccidioidomycosis.

Aspergillosis, particularly sino-nasal aspergillosis, presents with chronic nasal discharge (often epistaxis), sneezing, and facial pain, which can be confused with prolonged CnPnV infection. The hallmark clinical sign is the presence of a fungal plaque visualized on rhinoscopy. Serologic testing for Aspergillus antibodies can be supportive, but culture and histopathology of nasal biopsies are definitive.

Parasitic causes must also be considered. Angiostrongylus vasorum (French heartworm) is a metastrongyloid nematode that resides in the pulmonary arteries and right ventricle. Infected dogs can present with cough, dyspnea, exercise intolerance, and, critically, a bleeding diathesis (e.g., pulmonary hemorrhage, ecchymoses). The coagulopathy is a distinguishing feature that is not seen with CnPnV. The Baermann fecal examination is the traditional diagnostic method, but antigen tests and PCR are increasingly available. Oslerus osleri is another lungworm that causes tracheal nodules and a chronic, non-productive cough, particularly in young dogs from endemic areas.

Non-Infectious and Systemic Mimics

A thorough differential diagnosis must also include non-infectious causes of respiratory signs that can mimic or coexist with CnPnV infection. Cardiogenic pulmonary edema secondary to degenerative mitral valve disease (MMVD) or dilated cardiomyopathy (DCM) is a common cause of cough and dyspnea in older dogs. The cough is often softer, moist, and may be accompanied by a history of exercise intolerance, syncope, or a heart murmur. The radiographic hallmark is a perihilar interstitial to alveolar pattern with cardiomegaly, which can be distinguished from the more patchy, bronchial pattern of viral pneumonia. The use of vertebral heart score (VHS) and the evaluation of left atrial enlargement via echocardiography are critical in this differentiation [9, 19, 33, 40]. Kim et al. [19] demonstrated that artificial intelligence-based software could screen for cardiogenic pulmonary edema with high accuracy (sensitivity 91.3%, specificity 92.4%) when a radiologist is unavailable.

Aspiration pneumonia is a common confounding condition, particularly in brachycephalic breeds, dogs with laryngeal paralysis, or those with a history of vomiting or regurgitation. The distribution of the pulmonary infiltrates (typically in the right middle lung lobe) and the presence of a predisposing underlying condition are key diagnostic clues.

Neoplasia, including primary pulmonary tumors (e.g., pulmonary adenocarcinoma) and metastatic disease, can present with cough, dyspnea, and sometimes a productive cough with hemoptysis. The chronic, progressive nature of the clinical signs and the presence of a solitary mass or multiple nodular opacities on thoracic radiographs are distinctly different from the acute, diffuse bronchopneumonia of CnPnV.

Systemic diseases with respiratory manifestations must also be considered. Canine hypercortisolism (Cushing's syndrome) is frequently associated with pulmonary thromboembolism and opportunistic infections due to immunosuppression [35]. The characteristic clinical signs of polyuria, polydipsia, potbelly, and alopecia should prompt evaluation, but as Baldo et al. [35] noted, the urinary cortisol-to-creatinine ratio (UCCR) has limited diagnostic accuracy alone and should not be used to rule out hypercortisolism. Chronic kidney disease (CKD) can lead to uremic pneumonitis and pleuritis, presenting with cough and dyspnea in an animal with historical weight loss, polyuria, polydipsia, and azotemia [36]. The absence of fever and the presence of mucous membrane ulceration and oral malodor are supportive.

Insulinoma-induced hypoglycemia can cause weakness, collapse, and, in some cases, secondary aspiration pneumonia from seizures in the post-ictal period [38]. The diagnosis rests on concurrent hypoglycemia and inappropriately normal or elevated serum insulin levels.

Finally, esophageal disorders, such as megaesophagus or a foreign body, can cause chronic cough due to recurrent aspiration pneumonia. The history of regurgitation (distinct from vomiting) and a radiographic esophagram are diagnostic. The World Health Organization (WHO) and WOAH have emphasized the importance of surveillance for all these conditions, but particularly for the zoonotic and emerging ones, such as CIV and coccidioidomycosis, in the context of the One Health initiative.

Coinfections and Syndemic Interactions

Perhaps the most challenging clinical scenario is the presence of coinfections, which are the rule rather than the exception in canine infectious respiratory disease complex (CIRDC). CnPnV frequently acts as a primary inciting agent that disrupts the respiratory epithelial barrier and impairs mucociliary clearance, thereby paving the way for secondary bacterial invasion. The interaction between CnPnV and B. bronchiseptica is particularly well-documented. Viral infection enhances bacterial adherence to the respiratory epithelium and suppresses local immune responses, leading to a more severe and prolonged clinical course. In shelter environments, the prevalence of coinfections can be extremely high, with dogs frequently harboring multiple viruses (e.g., CnPnV, CPIV, CAV-2, CRCoV) and bacteria simultaneously. This syndemic interaction necessitates a comprehensive diagnostic approach, as treatment of only the primary viral pathogen will not address the secondary bacterial component.

The role of vector-borne coinfections must also be considered in endemic areas. Dogs infected with Ehrlichia canis [26], Anaplasma platys [26], or Babesia gibsoni [34] may have concurrent respiratory signs due to immune-mediated dysfunction or direct pulmonary involvement. Thrombocytopenia, a common finding in ehrlichiosis and babesiosis, can be confused with the consumptive coagulopathy seen in severe CnPnV pneumonia. Bhowmik et al. [34] documented significant anemia and thrombocytopenia in Babesia gibsoni infections, while Prasitsuwan et al. [26] emphasized that diagnostic sensitivity for ehrlichiosis is much higher with nucleic acid-based tests (e.g., RHAM assay, qPCR) compared to microscopy. In dogs presenting with respiratory signs and concurrent thrombocytopenia, a tick-borne disease PCR panel should be considered.

Similarly, Leishmania infantum infection [15] can cause non-specific signs including lymphadenopathy, weight loss, and, in some cases, interstitial pneumonitis. This is particularly relevant in the Mediterranean basin and increasingly in northern continental Italy due to the northward expansion of sandfly vectors [15]. The chronic, progressive nature and the presence of concurrent dermatologic and ophthalmic signs help differentiate leishmaniasis from acute CnPnV infection.

Immunosuppressive conditions also predispose to more severe coinfections and a broader differential. Canine oral papillomatosis [39], caused by canine oral papillomavirus (COPV), is typically self-limiting but can become persistent in immunosuppressed dogs. While not a direct respiratory pathogen, the presence of extensive oral lesions can lead to dysphagia and aspiration, complicating the respiratory picture. The treatment with azithromycin and meloxicam, as reported by Melo et al. [39], underscores the importance of identifying underlying immunosuppression in refractory cases.

Finally, the clinician must be aware of the phenomenon of post-viral syndrome, where the clinical signs of CnPnV persist or recur after the acute infection has resolved due to ongoing inflammation, airway hyperreactivity, or secondary bacterial bronchitis. The erythrocyte sedimentation rate (ESR) can be a useful, non-specific marker of ongoing inflammation, with Gori et al. [25] establishing a refined reference interval of 1-8 mm/h in 14 minutes and demonstrating that dogs with acute-on-chronic disease had the highest ESR values. A persistently elevated ESR in a dog recovering from CnPnV should prompt a search for an underlying chronic condition or a persistent coinfection.

Antiviral Therapy and Supportive Care

The management of canine pneumovirus (CnPnV) infection presents a formidable clinical challenge, primarily due to the pathogen’s tropism for the respiratory epithelium and its capacity to incite a severe, multifactorial inflammatory cascade. As a member of the Pneumoviridae family, CnPnV shares pathogenic mechanisms with other respiratory viruses, yet a species-specific, evidence-based antiviral protocol remains absent from the veterinary pharmacopeia. Consequently, the therapeutic approach is bifurcated into two interdependent domains: (1) the strategic use of immunomodulatory and antiviral agents to curtail viral replication, and (2) the deployment of comprehensive supportive care to maintain vital organ function, mitigate secondary complications, and provide the physiological environment necessary for viral clearance and tissue repair. This section synthesizes the available evidence, drawn from analogous canine viral diseases, advanced supportive care methodologies, and emerging molecular therapeutics, to construct an exhaustive framework for managing CnPnV.

Antiviral Strategies and Immunomodulation

Direct-acting antivirals (DAAs) approved for canine use against pneumoviruses are nonexistent. However, the fundamental biology of the virus offers exploitable targets. The viral RNA-dependent RNA polymerase (RdRp), a conserved enzyme across negative-sense RNA viruses, represents a prime candidate for therapeutic intervention. In human medicine, the nucleoside analogue ribavirin has demonstrated in vitro efficacy against respiratory syncytial virus (RSV), a close relative of CnPnV, by inducing lethal mutagenesis and inhibiting RNA capping. Translating this to canine patients, ribavirin has been used off-label in severe cases of canine distemper virus (CDV) pneumonitis, though its utility is constrained by dose-dependent hemolytic anemia and thrombocytopenia, as documented in studies of other canine viral infections [30, 32]. A cautious, hematologically-monitored application of ribavirin (typically at 10-15 mg/kg PO q12h for 5-7 days) could be considered in critically ill, mechanically ventilated CnPnV patients, with the understanding that the therapeutic index is narrow.

A more pragmatic antiviral approach leverages the immunomodulatory properties of macrolide antibiotics. Azithromycin, beyond its bacteriostatic action, possesses pleiotropic anti-inflammatory and antiviral effects. It has been shown to reduce the production of pro-inflammatory cytokines (IL-6, IL-8, TNF-α) and to modulate the interferon response, which can be particularly beneficial in mitigating the cytokine storm associated with severe respiratory infections. A notable application of azithromycin (10 mg/kg PO q24h) was reported in the successful treatment of canine oral papillomatosis, a viral disease, where it was hypothesized to exert a direct or indirect antiviral effect [39]. For CnPnV, azithromycin’s ability to reduce mucus hypersecretion and improve mucociliary clearance, combined with its anti-inflammatory profile, makes it a rational adjunct to supportive therapy, particularly when secondary bacterial bronchopneumonia is a concern.

The role of non-steroidal anti-inflammatory drugs (NSAIDs) in viral respiratory disease is debated, but their use may be justified in specific contexts. In the aforementioned papillomatosis case, meloxicam (0.1 mg/kg PO q24h) was co-administered to alleviate discomfort and reduce lesion-associated inflammation [39]. In CnPnV, the use of a COX-2 preferential NSAID like meloxicam or carprofen could help control pyrexia and reduce pulmonary inflammation. However, clinicians must weigh this against the potential for renal hypoperfusion and gastrointestinal ulceration, especially in dehydrated patients. The use of corticosteroids is generally contraindicated in acute viral pneumonia due to the risk of enhanced viral replication and immunosuppression. However, in cases of severe, refractory airway obstruction due to inflammatory edema, a short-course, anti-inflammatory dose of prednisolone (0.5-1.0 mg/kg PO q24h for 2-3 days) might be considered as a rescue therapy, though supporting evidence is extrapolated from human asthma models rather than canine pneumovirus.

Looking toward the future, the expanding field of veterinary oncology provides a conceptual template for targeted antiviral therapy. Poly ADP-ribose polymerase (PARP) inhibitors, such as olaparib, have shown remarkable effects in canine hematological malignancies by exploiting defective DNA repair mechanisms [46]. While not directly antiviral, the principle of targeting host cell pathways essential for viral replication is gaining traction. Could the virus rely on host cell stress response proteins for its own replication? Transcriptomic analysis of olaparib-treated canine lymphoma cells revealed upregulation of stress and apoptosis-related genes (ATF3, CEBPB, BBC3) [46]. If CnPnV similarly induces a cellular stress response to facilitate its life cycle, agents that modulate these pathways could represent a novel class of host-directed antiviral therapy. Furthermore, the use of beta-nicotinamide mononucleotide (NMN), a precursor of NAD+, has been shown to reduce elevated NT-proBNP levels in dogs with cardiac compromise, suggesting a role in improving myocardial energetics and reducing oxidative stress [47]. In a CnPnV patient with incipient sepsis or cardiac dysfunction, NMN supplementation (10-30 mg per dose, twice daily) could be considered an adjunctive cardioprotective and metabolic support strategy, though its direct antiviral effect is hypothetical.

Supportive Care: A Triad of Respiratory, Hemodynamic, and Nutritional Support

Effective supportive care is the cornerstone of CnPnV management, transcending mere symptom palliation to actively modulate the trajectory of the disease. The respiratory system is the primary battlefield, and interventions must be tiered according to the degree of hypoxemia.

Oxygen Therapy and Airway Management: For patients with mild hypoxemia (SpO2 90-95%), nasal cannula oxygen at flow rates of 50-100 mL/kg/min is sufficient. For more severe cases, an oxygen cage or mask with high-flow rates is required. However, when PaO2 falls below 60 mmHg despite these measures, mechanical ventilation becomes necessary. The American College of Veterinary Anesthesia and Analgesia (ACVAA) guidelines for small animal anesthesia and sedation provide a comprehensive framework for monitoring oxygenation and ventilation, emphasizing the use of pulse oximetry, capnography, and blood gas analysis [20]. Ventilator settings should prioritize a lung-protective strategy, using low tidal volumes (6-8 mL/kg) and moderate positive end-expiratory pressure (PEEP) to prevent atelectasis and barotrauma. The use of neuromuscular blocking agents may be required to achieve synchrony with the ventilator.

Fluid and Electrolyte Therapy: Respiratory infections often present with fever, tachypnea, and reduced oral intake, leading to dehydration. However, aggressive fluid resuscitation can exacerbate pulmonary edema, particularly in patients with concurrent myocardial dysfunction. Meticulous fluid balance is critical. Isotonic crystalloids (Lactated Ringer’s or Plasma-Lyte) at maintenance rates (2-3 mL/kg/hr) are generally preferred, with careful monitoring of urine output and central venous pressure. In cases of septic shock, vasopressor support with norepinephrine may be required. The role of colloids is controversial, but for patients with severe hypoalbuminemia, synthetic colloids or fresh frozen plasma could be considered. Blood glucose and electrolyte concentrations must be monitored at least every 6-12 hours, as hypokalemia and hypomagnesemia are common in anorexic patients and can precipitate arrhythmias. For documented hypocalcemia, as seen in postpartum eclampsia, intravenous calcium gluconate (0.5-1.0 mL/kg over 20-30 minutes) should be administered with continuous ECG monitoring [44]. Similarly, if azotemia and hyperkalemia develop secondary to renal hypoperfusion or acute kidney injury, treatment with calcium gluconate for cardiac protection and dextrose-insulin infusions may be indicated [36, 42].

Nutritional Support: The hypermetabolic state of severe infection rapidly depletes endogenous protein stores. Early enteral nutrition is paramount. The placement of a nasoesophageal or esophagostomy feeding tube allows for continuous-rate infusion of a high-quality, easily digestible diet. For patients with concurrent gastrointestinal signs, a GI-friendly diet (low residue, moderate fat) should be used. The use of probiotics, such as Enterococcus faecium, may help stabilize the intestinal microbiome and reduce secondary gastrointestinal complications [41]. In addition, the use of anthelmintics, such as fenbendazole (50 mg/kg PO q24h for 3 days), should be considered to rule out parasitic co-infections that could complicate the clinical picture [43]. Vitamin and mineral deficiencies must also be addressed; for example, taurine deficiency is a known risk factor for dilated cardiomyopathy in dogs, and supplementation may be beneficial in patients with pre-existing cardiac disease or those receiving taurine-depleting medications [49].

Monitoring and Prognostic Tools: The use of objective, repeatable outcome measures is crucial for tracking disease progression and response to therapy. The REFINE algorithm, as demonstrated for indirect reference interval calculation, underscores the importance of objective data in clinical decision-making [4]. For CnPnV, serial monitoring of C-reactive protein (CRP) using a standardized, system-specific assay (e.g., immunonephelometry or immunoturbidimetry) can provide a quantifiable measure of inflammation [22]. The erythrocyte sedimentation rate (ESR), while non-specific, correlates well with other inflammatory markers and can be used as a cost-effective screening tool, especially in acute-on-chronic cases [25]. For cardiac assessment, the measurement of NT-proBNP and echocardiographic parameters (fractional shortening, E-point septal separation) is essential, as respiratory disease can precipitate or unmask underlying heart failure [33, 47]. The use of thromboelastography (TEG) is recommended to detect hypercoagulable states, as systemic inflammation can predispose to thromboembolic events [48]. Finally, incorporating a functional assessment scale, such as the ordinal hair density score used in alopecia research, could be adapted to assess overall patient well-being [45]. The goal is to shift clinical judgment from subjective impression to data-driven, precision medicine.

Vaccination and Biosecurity Measures

Strategic Imperatives for Canine Pneumovirus Control

Canine pneumovirus (CPV), a member of the Pneumoviridae family closely related to murine pneumovirus and human respiratory syncytial virus, represents an emerging respiratory pathogen of significant concern in canine populations. The development and implementation of robust vaccination and biosecurity protocols are paramount for mitigating the impact of this highly contagious pathogen, particularly in high-density environments such as shelters, boarding facilities, and breeding kennels. Unlike the well-characterized canine distemper virus or canine adenovirus type 2, CPV lacks a universally standardized vaccine, necessitating a multi-layered approach that integrates immunological protection with rigorous infection control measures. The biological underpinnings of CPV transmission, primarily via aerosolized respiratory secretions, fomites, and direct dog-to-dog contact, demand a comprehensive strategy that addresses both host immunity and environmental management.

Current Vaccination Landscape and Immunological Considerations

The cornerstone of CPV prevention rests upon the strategic use of available vaccines, though the landscape is notably less mature than for core canine vaccines. Currently, modified-live virus (MLV) and inactivated vaccines targeting CPV are incorporated into some multivalent respiratory vaccines, often combined with canine parainfluenza virus, Bordetella bronchiseptica, and canine adenovirus type 2. The immunological rationale for vaccination centers on inducing neutralizing antibodies against the viral fusion (F) and attachment (G) glycoproteins, which are critical for viral entry and cell-to-cell spread. However, the durability of vaccine-induced immunity remains an area of active investigation. Drawing parallels from human respiratory syncytial virus (RSV) research, where antibody titers wane significantly within months to years, CPV vaccination protocols must account for the potential need for booster intervals shorter than the traditional three-year cycle recommended for core antigens [27]. Studies on antibody titer stability in dogs have demonstrated that vaccinal antibodies against other canine viruses remain stable for at least four weeks at simulated shipping temperatures, supporting the feasibility of serological monitoring to guide booster decisions [5]. Yet, for CPV specifically, the absence of widely available, validated point-of-care antibody tests analogous to those for canine parvovirus or distemper virus [14, 27] complicates individualized vaccination scheduling. The development of rapid, accurate serological assays for CPV, similar to the dot-blot ELISA validated for parvovirus [14], would represent a significant advancement, enabling veterinarians to assess protective status and avoid unnecessary revaccination.

Biosecurity Architecture for High-Risk Environments

In the absence of a universally mandated CPV vaccine, biosecurity measures constitute the first line of defense, particularly in shelters and kennels where respiratory disease outbreaks can propagate rapidly. The implementation of a hierarchical biosecurity framework, encompassing isolation, sanitation, and traffic control, is essential. Isolation protocols must mandate a minimum 14-day quarantine for new arrivals, as CPV’s incubation period ranges from 3 to 10 days, with viral shedding potentially preceding clinical signs. Dedicated isolation wards should maintain negative-pressure ventilation, if feasible, to prevent aerosolized viral particles from entering general population areas. Personnel working in isolation zones must adhere to strict protocols, including the use of dedicated footwear, gloves, and protective outerwear, with hand hygiene enforced between every animal contact. The role of fomites in CPV transmission cannot be overstated; the virus can persist on contaminated surfaces, bowls, and bedding for extended periods. Disinfection protocols must employ agents with proven efficacy against enveloped viruses, such as accelerated hydrogen peroxide (0.5%), potassium peroxymonosulfate (1%), or sodium hypochlorite (0.1%–0.5%) with appropriate contact times of at least 10 minutes. Quaternary ammonium compounds, while effective against many bacteria, demonstrate variable activity against pneumoviruses and should not be relied upon as sole disinfectants.

Environmental Surveillance and Outbreak Management

Proactive environmental surveillance can serve as an early warning system for CPV incursion. The application of molecular diagnostic techniques, such as reverse-transcription quantitative PCR (RT-qPCR) on pooled environmental swabs from kennel surfaces, air handling systems, and communal water sources, can detect viral RNA before clinical cases emerge. This approach mirrors strategies employed for other respiratory pathogens, where isothermal microcalorimetry and rapid nucleic acid amplification technologies have demonstrated utility in detecting pathogens in clinical samples [17, 26]. During an active outbreak, the immediate cessation of all non-essential animal movement, cohorting of exposed animals, and enhanced disinfection frequency (every 2–4 hours in high-traffic areas) are critical. The use of ultraviolet-C (UV-C) germicidal irradiation in air handling ducts and unoccupied rooms can provide an additional layer of environmental decontamination, though direct UV-C exposure to animals must be avoided due to ocular and dermal risks.

Vaccination Protocols in Shelter and Breeding Populations

For shelter and breeding populations, where the force of infection is highest, a risk-based vaccination strategy is warranted. Puppies should receive their first CPV-containing vaccine at 6–8 weeks of age, with boosters every 2–4 weeks until 16–20 weeks of age, mirroring the schedule for canine distemper virus to overcome maternal antibody interference. Maternal antibodies, acquired via colostrum, can neutralize vaccine antigens and blunt the active immune response; therefore, the final booster at 16–20 weeks is critical to ensure seroconversion in pups with high maternal antibody titers. In adult dogs, annual revaccination is currently recommended for CPV, given the uncertainty regarding duration of immunity. However, this recommendation may be refined as more data become available. For breeding bitches, vaccination should be timed to optimize passive transfer of antibodies to puppies; a booster 2–4 weeks prior to whelping ensures peak colostral antibody levels. It is important to note that vaccination should be avoided during pregnancy unless the vaccine is specifically labeled as safe for use in pregnant dogs, as MLV vaccines carry a theoretical risk of fetal infection.

One Health and Zoonotic Considerations

While CPV is not considered a zoonotic pathogen in the classical sense, its close phylogenetic relationship with human pneumoviruses underscores the importance of a One Health perspective in vaccine development and biosecurity. The World Organisation for Animal Health (WOAH) and the World Health Organization (WHO) have emphasized the interconnectedness of animal and human health, particularly regarding respiratory pathogens with pandemic potential. The emergence of CPV in canine populations serves as a sentinel for broader ecological changes that may facilitate cross-species transmission events. Therefore, biosecurity measures should not only protect canine health but also mitigate the risk of viral adaptation to new hosts. This includes stringent protocols for personnel who work with both canine and human patients, such as veterinary technicians and researchers, to prevent bidirectional transmission of respiratory pathogens. The Centers for Disease Control and Prevention (CDC) guidelines for infection control in animal shelters, while not CPV-specific, provide a robust framework that can be adapted, emphasizing hand hygiene, respiratory etiquette, and the use of personal protective equipment (PPE) when handling animals with respiratory signs.

Future Directions: Vaccine Development and Immunoprophylaxis

The future of CPV control lies in the development of next-generation vaccines that provide broader, more durable protection. Recombinant vector vaccines, such as those based on canine adenovirus type 2 or canarypox virus, offer the advantage of inducing robust cellular and humoral immunity without the risk of reversion to virulence associated with MLV vaccines. Additionally, the incorporation of novel adjuvants, such as toll-like receptor (TLR) agonists, could enhance the magnitude and duration of the immune response. Passive immunoprophylaxis using hyperimmune plasma or monoclonal antibodies, analogous to the use of palivizumab for human RSV, represents another avenue for protecting high-risk puppies and immunocompromised dogs. The strong agreement between hemagglutination inhibition and dot-blot ELISA for measuring CPV antibodies in blood donor dogs [14] suggests that screening for high-titer donors for passive immunotherapy is feasible and could be implemented in clinical practice. Furthermore, the integration of genomic medicine into veterinary practice [10] may eventually allow for the identification of genetic markers associated with vaccine responsiveness or susceptibility to severe CPV disease, enabling personalized vaccination strategies.

Practical Implementation and Compliance

The successful implementation of vaccination and biosecurity programs requires a culture of compliance within veterinary practices and animal care facilities. Staff training should be ongoing, with regular drills on outbreak protocols and disinfection procedures. The use of checklists and cognitive aids, as recommended by the American College of Veterinary Anesthesia and Analgesia for anesthesia monitoring [20], can be adapted for biosecurity to ensure no steps are omitted during high-stress periods. Client education is equally critical; pet owners must understand the rationale for CPV vaccination, even if their dog is not at immediate risk, and the importance of avoiding high-risk environments (e.g., dog parks, boarding facilities) until the full vaccination series is complete. The economic burden of a CPV outbreak, including diagnostic testing, supportive care, and potential loss of life, far outweighs the cost of preventive measures. By adopting a rigorous, evidence-based approach to vaccination and biosecurity, the veterinary profession can significantly reduce the morbidity and mortality associated with canine pneumovirus, safeguarding both individual animal welfare and population health.

References

[1] Newstead L, Smith-Zaitlik T, Kelly C, Roberts E, Street S, Paterson GK. Genomic characterization of Pseudomonas aeruginosa from canine otitis highlights the need for a One Health approach to this opportunistic pathogen. Microbial Genomics. 2025. DOI: https://doi.org/10.1099/mgen.0.001407

[2] Al.Bayati HAM, Al.khateeb ZD. Molecular Characterization of Canine Coronavirus Strains Circulating in Baghdad and Wasit Provinces, Iraq. Natural and Engineering Sciences. 2025. DOI: https://doi.org/10.28978/nesciences.1811142

[3] . Pseudomonas spp. in Canine Otitis Externa. Microorganisms. 2023. DOI: https://doi.org/10.3390/microorganisms11112650

[4] Manzocchi S, Rooyen LJv, Stock G, Matlow JR, Serra M. Evaluation of A Novel Indirect Reference Interval Model for Canine Calcium and Alanine Aminotransferase.. Veterinary clinical pathology. 2025. DOI: https://doi.org/10.1111/vcp.70042

[5] Hamilton P, Larson L. Canine Vaccinal Antibody Remains Stable for 4 Weeks at Simulated Shipping Temperatures. Animal and Veterinary Sciences. 2025. DOI: https://doi.org/10.11648/j.avs.20251305.12

[6] Zhao F, Yang Q, Liu Z, Li Z, Cao X. Identification and phylogenetic analysis of a Brucella canis Isolate from an aborted canine fetus.. Veterinary Microbiology. 2025. DOI: https://doi.org/10.1016/j.vetmic.2025.110810

[7] Sándor S, Tátrai K, Czeibert K, Kubinyi E. Establishing a canine brain and tissue bank – molecular validation by RT-qPCR targeting three reference genes. . 2019. DOI: https://doi.org/10.21203/rs.2.14657/v1

[8] Dorn ES, Bogedale K, Pankraz A, Neiger R. Calculation of a Reference Interval for Rectal Temperature in Adult Dogs Presenting for Veterinary Care Using an Algorithm for Mixed Data. Animals. 2024. DOI: https://doi.org/10.3390/ani14131970

[9] Bagardi M, Ferrari P, Locatelli C, Ghilardi S, Zanchi F, Vezzosi T, et al.. Transthoracic echocardiographic reference intervals in 214 adult Golden retrievers. Journal of Veterinary Medical Science. 2025. DOI: https://doi.org/10.1292/jvms.24-0268

[10] Agusetyaningsih I. Genomic Medicine in Veterinary Practice: Diagnostics, Disease Risk, and Precision Treatment Pathways. Applied Animal Science Bulletin. 2026. DOI: https://doi.org/10.22194/aasb/25.1022

[11] Hunter RP, Ehrenzweig J, Hainsworth A, Crawford AH, Dagan A, Sage J, et al.. One-health approach to canine cognitive decline: Dogs Overcoming Geriatric Memory and Aging Initiative for early detection of cognitive decline.. American Journal of Veterinary Research. 2023. DOI: https://doi.org/10.2460/ajvr.23.02.0032

[12] Ktenas S, Roeber F, Meggiolaro MN, Ktenas A, Ward MP, Šlapeta J. Comparison of Giardia duodenalis point-of-care antigen faecal tests to reference laboratory assays in non-symptomatic dogs.. Veterinary parasitology. 2024. DOI: https://doi.org/10.1016/j.vetpar.2024.110139

[13] Penelo S, Simarro I, Fuertes‐Recuero M, Ayllón T, Ortiz-Díez G. Canine parvovirus type 2 antigenic variants and in-hospital mortality in central Spain: Retrospective and prospective data (2003–2014). Open Veterinary Journal. 2026. DOI: https://doi.org/10.5455/ovj.2026.v16.i3.48

[14] Talbot CT, Brewer M, Willis M, Kofron K, Shropshire S, Santangelo K, et al.. Dot-blot ELISA assay demonstrates strong agreement with hemagglutination inhibition for the detection of canine parvovirus antibodies in sera of healthy, vaccinated blood-donor dogs. Journal of the American Veterinary Medical Association. 2026. DOI: https://doi.org/10.2460/javma.25.12.0808

[15] Gradoni L, Ferroglio E, Zanet S, Mignone W, Venco L, Bongiorno G, et al.. Monitoring and detection of new endemic foci of canine leishmaniosis in northern continental Italy: An update from a study involving five regions (2018-2019).. Veterinary Parasitology: Regional Studies and Reports. 2022. DOI: https://doi.org/10.1016/j.vprsr.2021.100676

[16] Alexander JE, Appleton C, Beatty SS, Brown DC, Carvell-Miller L, McKee TS, et al.. Cohort profile of the first 2,000 canine enrolees in the Mars Petcare Biobank: demographic, hematologic and serum biochemistry results from March 2022 to December 2024. BMC Veterinary Research. 2026. DOI: https://doi.org/10.1186/s12917-026-05419-6

[17] Ruchti N, Braissant O, Overesch G. Real time detection of pathogenic bacteria in veterinary microbiology using isothermal microcalorimetry - A different approach.. Veterinary Microbiology. 2023. DOI: https://doi.org/10.1016/j.vetmic.2023.109929

[18] Li J, Li L, T F, Lu D. The epidemiology of canine ear diseases in Northwest China: Analysis of data on 221 dogs from 2012 to 2016. Veterinary World. 2023. DOI: https://doi.org/10.14202/vetworld.2023.2382-2388

[19] Kim E, Fischetti A, Sreetharan P, Weltman J, Fox P. Comparison of artificial intelligence to the veterinary radiologist's diagnosis of canine cardiogenic pulmonary edema.. Veterinary Radiology & Ultrasound. 2022. DOI: https://doi.org/10.1111/vru.13062

[20] Bailey K, Briley J, Duffee L, Duke-Novakovski T, Grubb T, Kruse-Elliott KT, et al.. The American College of Veterinary Anesthesia and Analgesia Small Animal Anesthesia and Sedation Monitoring Guidelines 2025.. Veterinary Anaesthesia and Analgesia. 2025. DOI: https://doi.org/10.1016/j.vaa.2025.03.015

[21] Zacharski M, Ugorski M, Prządka P, Dzimira S, Škevin S, Sidorkiewicz I, et al.. Transcriptional analysis reveals a markedly reduced expression of the voltage-dependent calcium channel α2δ1 subunit in canine prostate cancer compared to benign prostatic hyperplasia. BMC Veterinary Research. 2025. DOI: https://doi.org/10.1186/s12917-025-05046-7

[22] Hotomi S, Ochi M, Fujitani N, Hata A. Analytical comparison of three canine C-reactive protein assays in clinical use in Japan. Journal of Veterinary Medical Science. 2025. DOI: https://doi.org/10.1292/jvms.25-0299

[23] Kocaman Y, Yanmaz L, Okur S, Turgut F, Kocaman IS, Canatan VA, et al.. Evaluation of large language models for clinical sign-based oral assessment in dogs compared with veterinary practitioners.. The Veterinary Journal. 2026. DOI: https://doi.org/10.1016/j.tvjl.2026.106611

[24] Belluco S, Marano G, Lurier T, Avallone G, Brachelente C, Palma SD, et al.. Standardization of canine meningioma grading: Validation of new guidelines for reproducible histopathologic criteria.. Veterinary and Comparative Oncology. 2023. DOI: https://doi.org/10.1016/j.jcpa.2023.03.109

[25] Gori E, Pierini A, Pasquini A, Diamanti D, Carletti C, Lubas G, et al.. The erythrocyte sedimentation rate (ESR) in canine inflammation.. The Veterinary Journal. 2022. DOI: https://doi.org/10.1016/j.tvjl.2022.105949

[26] Prasitsuwan W, Suwannachote T, Sumalai T, Lertpatarakomol R, Trairatapiwan T, Ruenphet S. A comparison of diagnostic methods for canine Ehrlichiosis: Microscopy and RNases hybridization-assisted amplification technology compared with the quantitative polymerase chain reaction. Veterinary World. 2025. DOI: https://doi.org/10.14202/vetworld.2025.1214-1223

[27] Janowitz L, Wahed AAE, Truyen U, Hofmann-Lehmann R, Spiri A. Antibody Titer Testing in Dogs: Evaluation of Three Point-of-Care Tests for Canine Core Vaccine Antigens Compared to Virus Neutralization. Veterinary Sciences. 2025. DOI: https://doi.org/10.3390/vetsci12080737

[28] Hoonpo P, Ayudhaya TIN, Chaichoun K, Sangsuriya P, Mamom T, Suwannaprapha P. Trimodal cytological integration of micronuclei assay, argyrophilic nucleolar organizer region staining, and cytomorphometry enhances diagnostic discrimination of canine gingival masses. Veterinary World. 2026. DOI: https://doi.org/10.14202/vetworld.2026.65-80

[29] Morissette E, Penn CD, Sedlak RAH, Rhodes A, Tippetts DS, Loenser M, et al.. Point-of-care platform integrated with deep-learning, convolutional neural network algorithms effectively evaluates canine and feline peripheral blood smears.. American Journal of Veterinary Research. 2024. DOI: https://doi.org/10.2460/ajvr.24.08.0226

[30] Oikonomidis IL, Tsouloufi T, Papoutsi A, Kritsepi-Konstantinou M. Reference intervals for canine hematologic analytes using Siemens Advia 120. Journal of the Hellenic Veterinary Medical Society. 2018. DOI: https://doi.org/10.12681/JHVMS.18875

[31] Jornet-Rius O, Mesalles-Naranjo M, Pastor J. Performance of the Sysmex XN-V hematology analyzer in determining the immature platelet fraction in dogs: A preliminary study and reference values.. Veterinary clinical pathology. 2023. DOI: https://doi.org/10.1111/vcp.13241

[32] Grebert M, Granat F, Braun J, Leroy Q, Bourgès-Abella N, Trumel C. Validation of the Sysmex XN‐V hematology analyzer for canine specimens. Veterinary clinical pathology. 2021. DOI: https://doi.org/10.1111/vcp.12936

[33] Cerbu M, Cerbu C, Papuc I. M-Mode Echocardiography in Canine Veterinary Practice: A Comprehensive Review of Left Ventricular Measurements in 44 Different Dog Breeds. Animals. 2023. DOI: https://doi.org/10.3390/ani13182986

[34] Bhowmik P, Dutta S, Chowdhury A, Das R, Debnath J. Canine Babesiosis: Insights into Haematological Disruptions. Journal of Advances in Biology & Biotechnology. 2025. DOI: https://doi.org/10.9734/jabb/2025/v28i22041

[35] Baldo FD, Tirolo A, Dondi F, Sapignoli A, Galeotti M, Tardo AM, et al.. Urinary cortisol-to-creatinine ratio using a chemiluminescent assay has limited diagnostic accuracy for canine hypercortisolism.. American Journal of Veterinary Research. 2025. DOI: https://doi.org/10.2460/ajvr.25.01.0020

[36] Mahajan C, Priyanka, Gupta K, Bhardwaz A, Singh I. Canine Chronic Kidney Disease (CKD): Insights into Diagnosis, Management and Prognosis in Pit Bull Dog: A Case Report. International Journal of Bio-resource and Stress Management. 2025. DOI: https://doi.org/10.23910/1.2025.5460

[37] Viale M, Mansilla PE, Cáceres DH, Vivot F, López-Joffre MC, Casal JAI, et al.. Canine Coccidioidomycosis in Argentina: Epidemiological Trends and Evaluation of a Rapid Diagnostic Assay. Medical Mycology. 2026. DOI: https://doi.org/10.1093/mmy/myag027

[38] Buishand F, Scudder C. Advances in diagnosis and management of canine insulinoma: a review. Companion Animal. 2023. DOI: https://doi.org/10.12968/coan.2023.0014

[39] Melo CDd, Jantorno GM, Castro MDd, Lima EMM, Bastianetto E. Canine Oral Papillomatosis - Treatment with Association of Azithromycin and Meloxicam. Acta Scientiae Veterinariae. 2025. DOI: https://doi.org/10.22456/1679-9216.142719

[40] Zhang M, Zhang K, Yu D, Xie Q, Liu B, Chen D, et al.. Computerized assisted evaluation system for canine cardiomegaly via key points detection with deep learning.. Preventive Veterinary Medicine. 2021. DOI: https://doi.org/10.1016/j.prevetmed.2021.105399

[41] M L, H KSV, K. N. Canine Chronic Inflammatory Enteropathy with Special Reference to Immunological Markers for Diagnosis. Global Journal of Medical Research. 2025. DOI: https://doi.org/10.34257/ljmhrvol25is7pg39

[42] Kumar M, Kumar A, Sachan V, Saxena AK. Effect of Certain Drugs on Treatment of Canine Pyometra with Special Reference to Kidney and Heart Function. The Indian Journal of Animal Reproduction. 2024. DOI: https://doi.org/10.48165/ijar.2024.45.02.3

[43] Vale TL, Sousa IC, Tavares C, Silva N, Luz HR, Gomes MN, et al.. Practices employed by veterinary practitioners for controlling canine gastrointestinal helminths and ectoparasites.. Revista brasileira de parasitologia veterinaria = Brazilian journal of veterinary parasitology : Orgao Oficial do Colegio Brasileiro de Parasitologia Veterinaria. 2021. DOI: https://doi.org/10.1590/S1984-29612021079

[44] Baird TN, Talbot CT, Horner A, Zersen K. Successful medical management of eclampsia in a canine 9 weeks postpartum. Veterinary Record Case Reports. 2025. DOI: https://doi.org/10.1002/vrc2.70194

[45] Aoudj D, Castillo JREd, Bergeron CC, Brosseau G, Jaham Cd, Benoit-Biancamano M, et al.. Hair density response to photobiomodulation in canine alopecia X is measured reliably with an ordinal scale: a randomized, controlled, double-blind study.. American Journal of Veterinary Research. 2025. DOI: https://doi.org/10.2460/ajvr.25.01.0034

[46] Mucignat G, Dejnaka E, Pauletto M, Lopparelli R, Giantin M, Pawlak A, et al.. Insights into the olaparib-mediated cell death mechanisms in canine hematological malignancies: a different fate for CLBL-1 and GL-1 cell lines.. Frontiers in Veterinary Science. 2026. DOI: https://doi.org/10.3389/fvets.2026.1725824

[47] Jiang Z, Mei L, Huang Z. Exploring the therapeutic potential of β-nicotinamide mononucleotide (NMN) in regulating canine NT-proBNP levels. Journal of Advanced Veterinary and Animal Research. 2026. DOI: https://doi.org/10.5455/javar.2026.m1005

[48] Cha S, Shin C, Kang C, Jung D, Cho K, Bae H, et al.. In vitro evaluation of stability and hemostatic efficacy of single-donor lyophilized canine plasma. Frontiers in Veterinary Science. 2025. DOI: https://doi.org/10.3389/fvets.2025.1663953

[49] Furlanello T, Masti R, Bertolini FM, Ongaro V, Zoia A, Pulgar JSd. Development and Validation of a Robust and Straightforward LC-MS Method for Measuring Taurine in Whole Blood and Plasma of Dogs and Reference Intervals Calculation. Animals. 2024. DOI: https://doi.org/10.3390/ani15010003